<table border="1" cellpadding="1" cellspacing="1" class="left" height="3064" summary="list of protocols">
<caption><strong>Neoadjuvant / Adjuvant Treatments</strong></caption>
<tbody>
<tr align="left" valign="top">
<td><strong>Regimen Name</strong></td>
<td><strong>Indication</strong></td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Anastrozole</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/254.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00254b</strong></p>
<p>Adjuvant treatment of hormone receptor positive early invasive breast cancer in post-menopausal women.</p>
<p><strong>00254c</strong></p>
<p>Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Capecitabine Monotherapy*</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/216.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00216f</strong></p>
<p>Adjuvant treatment of stage I to IIIB, triple negative breast cancer (TNBC) in patients with residual invasive disease after neoadjuvant chemotherapy treatment</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CARBOplatin (AUC6) and Weekly PACLitaxel (80mg/m<sup>2</sup>) followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy-Triple Negative Breast Cancer Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/348.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00348a</strong></p>
<p>Neoadjuvant treatment of triple negative breast carcinoma.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Cyclophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) Therapy  21 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/381.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00381a</strong></p>
<p>Adjuvant treatment for breast carcinoma in patients who are considered unsuitable for anthracycline therapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Cyclophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) Therapy  28 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/378.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00378a</strong></p>
<p>Adjuvant treatment for breast carcinoma in patients who are considered unsuitable for anthracycline therapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Cyclophosphamide (oral) Methotrexate and 5-Fluorouracil (CMF) Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/377.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00377a</strong></p>
<p>Adjuvant treatment for breast carcinoma in patients who are considered unsuitable for anthracycline therapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>DOCEtaxel/Cyclophosphamide (TC) Therapy-21 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/250-docetaxel-cyclophosphamide-tc-therapy-21-day.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00250a</strong></p>
<p>Adjuvant treatment of patients with high risk node-positive or node-negative early operable breast cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>DOCEtaxel, CARBOplatin and Trastuzumab (TCH)-21 days</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/258.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00258a</strong></p>
<p>Adjuvant treatment HER2 positive early breast cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>DOCEtaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/722-docetaxel-carboplatin-trastuzumab-and-pertuzumab-tchp-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00722a</strong></p>
<p>Neoadjuvant treatment of adult patients with HER2-<br/>positive locally advanced, inflammatory or early breast<br/>cancer at high risk of recurrence</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>DOCEtaxel, CARBOplatin, Trastuzumab (S/C) and Pertuzumab (TCH(S/C)P) Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/731-docetaxel-carboplatin-trastuzumab-s-c-and-pertuzumab-tch-s-c-p-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00731a</strong></p>
<p>Neoadjuvant treatment of adult patients with HER2-<br/>positive locally advanced, inflammatory or early breast<br/>cancer at high risk of recurrence</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>DOXOrubicin and Cyclophosphamide (AC 60/600) Therapy - 21 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/252.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00252a</strong></p>
<p>Adjuvant Treatment of High Risk Node Negative or Node Positive Breast Cancer</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>DOXOrubicin, Cyclophosphamide followed by weekly PACLitaxel Therapy (AC-T)</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/260-doxorubicin-cyclophosphamide-followed-by-weekly-paclitaxel-therapy-ac-t-.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00260a</strong></p>
<p>Neoadjuvant or Adjuvant Treatment of High Risk Node<br/>Negative or Node Positive Breast Cancer</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day  followed by PACLitaxel (80) 7 day Therapy (DD AC-T)</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/485.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00485a </strong></p>
<p>Adjuvant Treatment of High Risk Node Negative or Node Positive Breast Cancer</p>
<p><strong>00485b</strong></p>
<p>Neoadjuvant Treatment of High Risk Node Negative or Node Positive Breast Cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day  followed by PACLitaxel (175) 14 day Therapy (DD AC-T)</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/278-dose-dense-doxorubicin-cyclophosphamide-ac-60-600-14-day-followed-by-paclitaxel-175-14-day-therapy-dd-ac-t-.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00278a</strong></p>
<p>Adjuvant treatment of High Risk Node Negative or Node Positive Breast Cancer</p>
<p><strong>00278b</strong></p>
<p>Neoadjuvant treatment of High Risk Node Negative or Node Positive Breast Cancer</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/432-doxorubicin-cyclophosphamide-followed-by-weekly-paclitaxel-80-and-weekly-trastuzumab-therapy-ac-th-.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00432a</strong></p>
<p>Adjuvant Treatment of HER2 positive, High Risk Node Negative or Node Positive Breast Cancer.</p>
<p><strong>00432b</strong></p>
<p>Neoadjuvant Treatment of HER2 positive, High Risk Node Negative or Node Positive Breast Cancer.</p>
<p> </p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (DD AC-TH)</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/433-dose-dense-doxorubicin-cyclophosphamide-ac-60-600-14-day-followed-by-weekly-paclitaxel-80-and-weekly-trastuzumab-therapy-dd-ac-th-.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00433a</strong></p>
<p>Adjuvant Treatment of HER2 positive, High Risk Node Negative or Node Positive Breast Cancer.</p>
<p><strong>00433b</strong></p>
<p>Neoadjuvant Treatment of HER2 positive, High Risk Node Negative or Node Positive Breast Cancer<strong></strong></p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day  followed by PACLitaxel (175) 14 day and Trastuzumab Therapy </strong><strong>(DD AC-TH)</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/316-dose-dense-doxorubicin-cyclophosphamide-ac-60-600-14-day-followed-by-paclitaxel-175-14-day-and-trastuzumab-therapy-dd-ac-th-.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00316a</strong></p>
<p>Adjuvant Treatment of HER2 positive, High Risk Node Negative or Node Positive Breast Cancer.</p>
<p><strong>00316b</strong></p>
<p>Neoadjuvant Treatment of HER2 positive, High Risk Node Negative or Node Positive Breast Cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>epiRUBicin 90 and Cyclophosphamide (EC90) Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/262.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00262a</strong></p>
<p>Adjuvant treatment for operable breast carcinoma</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Exemestane Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/376.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00376a</strong></p>
<p>Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.</p>
<p><strong>00376b</strong></p>
<p>Extended adjuvant treatment of hormone-dependent invasive breast cancer in postmenopausal women who have received prior adjuvant endocrine therapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>5-Fluorouracil, epiRUBicin 100 and Cyclophosphamide (FEC 100) Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/265.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00265a</strong></p>
<p>Neoadjuvant treatment for breast carcinoma</p>
<p><strong>00265b</strong></p>
<p>Adjuvant treatment for breast carcinoma</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Letrozole Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/371.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00371a</strong></p>
<p>Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.</p>
<p><strong>00371b</strong></p>
<p>Extended adjuvant treatment of hormone-dependent-invasive breast cancer in postmenopausal women who have received prior adjuvant endocrine therapy for 5 years.</p>
<p><strong>00371d</strong></p>
<p>Neo-adjuvant treatment of postmenopausal women with hormone receptor positive breast cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong><strong>Neratinib Therapy</strong></strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/720.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00720a</strong></p>
<p>Extended adjuvant treatment of adults with early-stage hormone receptor-positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>PACLitaxel (80) and Trastuzumab Therapy – 7 day (12 weeks)</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/512-paclitaxel-80-and-trastuzumab-therapy-%E2%80%93-7-day-12-weeks-.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00512a</strong></p>
<p>Adjuvant Treatment of HER2 positive, Node-Negative Breast Cancer of tumor size ≤3cm</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Pertuzumab and Trastuzumab (Phesgo®) Maintenance  Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/785-pertuzumab-and-trastuzumab-phesgo-maintenance-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00785a</strong></p>
<p>Pertuzumab/ trastuzumab (Phesgo®) for the maintenance treatment of adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, where this is a continuation of treatment for patients who have completed the chemotherapy component of the treatment.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>DOCEtaxel, CARBOplatin and Pertuzumab/Trastuzumab (Phesgo®)(TCHP) Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/789-docetaxel-carboplatin-and-pertuzumab-trastuzumab-phesgo-tchp-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00789a</strong></p>
<p>Neoadjuvant treatment of adult patients with HER2-positive locally advanced, inflammatory or early breast cancer at high risk of recurrence.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Pertuzumab/Trastuzumab (Phesgo®), PACLitaxel and CARBOplatin Therapy (TRAIN-2)</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/790-pertuzumab-trastuzumab-phesgo-paclitaxel-and-carboplatin-therapy-train-2-.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00790a</strong></p>
<p>Neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Pertuzumab and Trastuzumab (Phesgo®) and DOCEtaxel Therapy - 21 day cycle</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/796-pertuzumab-and-trastuzumab-phesgo-and-docetaxel-therapy-21-day-cycle.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00796a</strong></p>
<p>Pertuzumab/ trastuzumab (Phesgo®)  is indicated in combination with DOCEtaxel in adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Pertuzumab and Trastuzumab (Phesgo®) and PACLitaxel Therapy - 21 day cycle</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/797-pertuzumab-trastuzumab-phesgo-and-weekly-paclitaxel-therapy-21-day-cycle.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00797a</strong></p>
<p>Pertuzumab/trastuzumab (Phesgo®)  is indicated in combination with PACLitaxel  in adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease where patients are intolerant of, have had significant toxicity to or are deemed clinically unsuitable for DOCEtaxel</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Pertuzumab and Trastuzumab and Chemotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/350 pertuzumab and trastuzumab and chemotherapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00350a</strong></p>
<p>Pertuzumab in combination with trastuzumab and<br/>chemotherapy for the neoadjuvant treatment of adult<br/>patients with HER2-positive, locally advanced,<br/>inflammatory, or early stage breast cancer at high risk of<br/>recurrence</p>
<p><strong>00350b</strong></p>
<p>Pertuzumab in combination with trastuzumab and<br/>chemotherapy for the adjuvant treatment of adult<br/>patients with HER2-positive breast cancer at high risk of<br/>recurrence</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Tamoxifen</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/253tamoxifen.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00253a</strong></p>
<p>Adjuvant treatment of oestrogen receptor positive breast cancer in pre- or post-menopausal women.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Trastuzumab (IV) Monotherapy - 21 days</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/200-trastuzumab-iv-monotherapy-21.pdf">Regimen</a></p>
</td>
<td>
<p> </p>
<p><strong>00200b</strong></p>
<p>HER2 positive early breast cancer (EBC)</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Trastuzumab Subcutaneous 21 days - Early Breast Cancer</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/285.pdf">Regimen</a></p>
</td>
<td>
<p>HER2 positive early breast cancer (EBC):</p>
<p><strong>00285a</strong></p>
<p>Following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable)</p>
<p><strong>00285b</strong></p>
<p>Following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel</p>
<p><strong>00285c</strong></p>
<p>In combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.</p>
<p><strong>00285d</strong></p>
<p>In combination with neoadjuvant chemotherapy followed by adjuvant trastuzumab therapy, for locally advanced (including inflammatory) disease or tumours &gt; 2 cm in diameter</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Trastuzumab Emtansine (Kadcyla<sup>®</sup>) Early Breast Cancer Therapy-21 days</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/659-trastuzumab-emtansine-kadcyla-early-breast-cancer-therapy-21-days.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00659a</strong></p>
<p>As a single agent is indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Zoledronic Acid</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/545-zoledronic-acid-monotherapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00545a</strong></p>
<p>Adjuvant treatment of breast cancer in endocrine depleted pre- or post menopausal women</p>
</td>
</tr>
</tbody>
</table><table border="1" cellpadding="1" cellspacing="1" class="left" height="1728" summary="list of protocols">
<caption><strong>Locally Advanced / Metastatic Regimens</strong></caption>
<thead>
<tr align="left" valign="top">
<th id="th0915DEB80000">Regimen Name</th>
<th id="th0915DEB80001">Indication</th>
</tr>
</thead>
<tbody>
<tr align="left" valign="top">
<td>
<p><strong>Anastrozole</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/254.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00254a</strong></p>
<p>Treatment of hormone receptor positive locally advanced or metastatic breast cancer in post-menopausal women</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Atezolizumab and nab-PACLitaxel Therapy  </strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/688.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00688a</strong></p>
<p>Treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Bevacizumab 10 mg/kg –14 days</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/212.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00212c</strong></p>
<p>In combination with paclitaxel is indicated for first-line treatment of adult patients with HER2-negative metastatic breast cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Bevacizumab 15 mg/kg – 21 days</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/215.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00215e</strong></p>
<p>In combination with paclitaxel is indicated for first-line treatment of adult patients with HER2-negative metastatic breast cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Bevacizumab 10mg/kg and PACLitaxel 80mg/m2 Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/00738-bevacizumab-10mg-kg.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00738a</strong></p>
<p>In combination with PACLitaxel for the treatment of adult patients with triple negative or HER<sup>2</sup>-negative metastatic breast cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Capecitabine Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/216.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00216a</strong></p>
<p>Treatment of patients with locally advanced or metastatic breast cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CARBOplatin (AUC 4-6) Monotherapy- 21 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/carboplatin-auc4-6-monotherapy-21-days1carboplatin%20auc4-6%20monotherapy-21%20days.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00261j*</strong></p>
<p>Metastatic breast carcinoma.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CARBOplatin (AUC 4-6) Monotherapy- 28 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/251.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00251j*</strong></p>
<p>Metastatic breast carcinoma.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Cyclophosphamide (oral) Methotrexate and 5-Fluorouracil (CMF) Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/377.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00377b</strong></p>
<p>Metastatic breast carcinoma.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Cyclophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) Therapy 21 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/381.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00381b</strong></p>
<p>Metastatic breast carcinoma.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Cyclophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) Therapy 28 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/378.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00378b</strong></p>
<p>Metastatic breast carcinoma.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Denosumab 120mg Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/741-densosumab-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00741a</strong></p>
<p>For the prevention of skeletal related events in adult patients with malignancies involving bone.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Dose Dense Doxorubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and Trastuzumab 21 day Therapy (DD AC-TH)</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/745-dose-dense-doxorubicin-cyclophosphamide.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00745a</strong></p>
<p>Adjuvant Treatment of HER2 positive, High Risk Node Negative or Node Positive Breast Cancer</p>
<p><strong>00745b</strong></p>
<p>Neoadjuvant Treatment of HER2 positive, High Risk Node Negative or Node Positive Breast Cancer<strong></strong></p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>DOCEtaxel Monotherapy 75mg/m<sup>2</sup> – 21 day cycle</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/203.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00203h</strong></p>
<p>Treatment of advanced breast cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>DOCEtaxel Monotherapy 100mg/m<sup>2</sup> – 21 day cycle</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/202.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00202a</strong></p>
<p>Docetaxel monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>DOXOrubicin 50mg/m<sup>2</sup>/DOCEtaxel 75mg/m<sup>2</sup>(AT 50/75) Therapy– 21 day cycle</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/423.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00423a</strong></p>
<p>Treatment of Locally Advanced or Metastatic Breast Carcinoma.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>DOXOrubicin (Pegylated Liposomal) 50mg/m<sup>2</sup> (CAELYX)<sup>®</sup>-28 days</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/205-pegylated-liposomal-doxorubicin-50mg-m2-caelyx-%C2%AE-28-days-regimen.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00205a</strong></p>
<p>Monotherapy for patients with metastatic breast cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>epiRUBicin 75 + Cyclophosphamide (EC75) Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/263.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00263a</strong></p>
<p>Metastatic breast carcinoma.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>eriBULin Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/228-eribulin-monotherapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00228a</strong></p>
<p>Treatment of locally advanced or metastatic breast cancer which has progressed after at least one chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>eriBULin Monotherapy – 28 Day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/eribulin-monotherapy-28-day743.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00743a</strong></p>
<p>Treatment of locally advanced or metastatic breast cancer which has progressed after at least one chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Everolimus and Exemestane Therapy </strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/322-everolimus-and-exemestane-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00322a</strong></p>
<p>Treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Exemestane Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/376.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00376c</strong></p>
<p>Advanced breast cancer after relapse or disease progression, in women with natural or artificially induced postmenopausal endocrine status.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>5-Fluorouracil, epiRUBicin 50 and Cyclophosphamide (FEC50) Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/269.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00269a</strong></p>
<p>Metastatic breast carcinoma</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Fulvestrant Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/361.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00361a</strong></p>
<p>Treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant anti-oestrogen therapy.</p>
<p><strong>00361b</strong></p>
<p>Treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease progression on or after adjuvant anti-oestrogen therapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Gemcitabine and CARBOplatin (AUC2) Therapy - 21 days</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/430-gemcitabine-and-carboplatin-auc2-therapy-21-days.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00430a</strong></p>
<p>Treatment of locally recurrent metastatic triple negative breast cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Lapatinib and Capecitabine</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/217.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00217a</strong></p>
<p>Treatment of adult patients with breast cancer, whose tumours overexpress HER2 in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Letrozole Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/371.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00371c</strong></p>
<p>Advanced breast cancer after relapse or disease progression, in women with natural or artificially induced postmenopausal endocrine status.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>PACLitaxel Monotherapy 80mg/m<sup>2 </sup>Day 1, 8, 15 and 22 – 28 Day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/226-paclitaxel-monotherapy-80mg-m2-7day-cycle.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00226a*</strong></p>
<p>Treatment of metastatic breast carcinoma (mBC) in patients who have either failed or are not candidates for standard, anthracycline-containing therapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>PACLitaxel 80mg/m<sup>2</sup> Day 1, 8 and 15 Monotherapy-28 Day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/621.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00621b </strong></p>
<p>Treatment of metastatic breast carcinoma (mBC) in patients who have either failed or are not candidates for standard, anthracycline-containing therapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>nab-PACLitaxel Monotherapy – 21 day cycle</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/230-nab-paclitaxel-abraxane%C2%AE-monotherapy-%E2%80%93-21-day-cycle.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00230a</strong></p>
<p>Treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>nab-PACLitaxel Weekly Monotherapy - 28 Day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/nab-paclitaxel-weekly-monotherapy28-day.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00736a</strong></p>
<p>Treatment of metastatic breast carcinoma (mBC) in patients who have<br/>either failed or are not candidates for standard, anthracycline-containing therapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Palbociclib Therapy-28day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/414-palbociclib-therapy-28-days.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00414a </strong></p>
<p>Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor</p>
<p><strong>00414b</strong></p>
<p>Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in women who have received prior endocrine therapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Pertuzumab and Trastuzumab and DOCEtaxel Therapy-21 day cycle</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/204-pertuzumab-and-trastuzumab-and-docetaxel-therapy-21-day-cycle.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00204a</strong></p>
<p>Pertuzumab is indicated in combination with trastuzumab and DOCEtaxel in adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti HER2 therapy or chemotherapy for their metastatic disease.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Pertuzumab Trastuzumab and weekly PACLitaxelTherapy-21 day cycle</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/507.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00507a</strong></p>
<p>Pertuzumab is indicated in combination with trastuzumab and PACLitaxel  in adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease where patients are intolerant of, have had significant toxicity to or are deemed clinically unsuitable for DOCEtaxel.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Pertuzumab Trastuzumab, PACLItaxel and CARBO</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/775-pertuzumab-trastuzumab-paclitaxel-and-carboplatin-therapy-train-2-.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00775a</strong></p>
<p>Neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Pertuzumab and Trastuzumab Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/726-pertuzumab-trastuzumab-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00726a</strong></p>
<p>Pertuzumab in combination with trastuzumab for the maintenance treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, where this is a continuation of treatment for patients who have completed the chemotherapy component of the treatment.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Pertuzumab Trastuzumab and Vinorelbine</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/526-pertuzumab-trastuzumab-and-vinorelbine.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00526a</strong></p>
<p>­­­­Pertuzumab in combination with trastuzumab and vinorelbine for the treatment of adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease where patients are deemed clinically unsuitable for taxane based therapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Ribociclib Therapy-28 days</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/525-ribociclib-therapy-28-day.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00525a</strong></p>
<p>Treatment of postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer as initial endocrine-based therapy in combination with an aromatase inhibitor.</p>
<p><strong>00525b</strong></p>
<p>Treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine based therapy or in women who have received prior endocrine therapy.</p>
<p>In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Talazoparib Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/605-talazoparib-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00605a</strong></p>
<p>Talazoparib is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy or be considered unsuitable for endocrine-based therapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Tamoxifen</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/253tamoxifen.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00253b</strong></p>
<p>Treatment of oestrogen receptor positive advanced breast cancer in pre- or post-menopausal women.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Trastuzumab (IV) Monotherapy - 7 days</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/201.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00201a</strong></p>
<p>The treatment of patients with HER2 positive metastatic breast cancer (MBC).</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Trastuzumab (IV) Monotherapy - 21 days</strong></p>
<p> <a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/200-trastuzumab-iv-monotherapy-21.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00200a</strong></p>
<p>HER2 positive metastatic breast cancer (MBC)</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Trastuzumab Subcutaneous-21 days - Metastatic Breast Carcinoma</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/272.pdf">Regimen</a></p>
</td>
<td>
<p>HER2 positive metastatic breast cancer (MBC):</p>
<p><strong>00272a</strong></p>
<p>As monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments.</p>
<p><strong>00272b</strong></p>
<p>In combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable.</p>
<p><strong>00272c</strong></p>
<p>In combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.</p>
<p><strong>00272d</strong></p>
<p>In combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Trastuzumab Emtansine (Kadcyla®)-21 days</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/206.pdf">Regimen</a></p>
</td>
<td>
<p><strong><strong>00206a </strong></strong></p>
<p>Treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination.</p>
<p>Patients should have either:</p>
<ul>
<li>Received prior therapy for locally advanced or metastatic disease, or</li>
<li>Developed disease recurrence during or within six months of completing adjuvant therapy.</li>
</ul>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Intravenous Vinorelbine Therapy-21 days</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/232-intravenous-vinorelbine-therapy-21-days.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00232a</strong></p>
<p>Advanced breast cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Oral Vinorelbine Monotherapy-7days</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/259.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00259a</strong></p>
<p>Advanced breast cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Zoledronic Acid Therapy-28 days</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/zoledronic-acid-28days-v1-723.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00723a</strong></p>
<p>Prevention of skeletal related events in malignancies involving bone metastases</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Zoledronic Acid Therapy-3 monthly</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/zoledronic-acid-3-monthly-v1-724.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00724a</strong></p>
<p>Prevention of skeletal related events in malignancies involving bone metastases</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Zoledronic Acid Therapy-6 monthly</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/zoledronic-acid-6-monthly-v1-725.pdf">Regimen</a><strong></strong></p>
</td>
<td>
<p><strong>00725a</strong></p>
<p>Prevention of skeletal related events in malignancies involving bone metastases</p>
</td>
</tr>
</tbody>
</table><table border="1" cellpadding="1" cellspacing="1" style="width: 813px;">
<tbody>
<tr>
<td style="width: 442px;"><strong>Regimen Name</strong></td>
<td style="width: 368px;"><strong>Indication</strong></td>
</tr>
<tr>
<td style="width: 442px;">
<p><strong>Axicabtagene ciloleucel (Yescarta®) (CAR-T) DLBCL and PMBCL</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/car-t-therapy/717-axicabtagene-dlbcl-and-pmbcl.pdf">Regimen</a></p>
</td>
<td style="width: 368px;">
<p><strong>00717a</strong></p>
<p>Treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy.</p>
</td>
</tr>
<tr>
<td style="width: 442px;">
<p><strong>Fludarabine &amp; Cyclophosphamide Lymphodepletion for Axicabtagene ciloleucel (Yescarta®)</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/car-t-therapy/608-fludarabine-cyclophosphamide-lymphodepletion-yescarta-.pdf">Regimen</a></strong></p>
</td>
<td style="width: 368px;">
<p><strong>00608a</strong></p>
<p>Lymphodepletion chemotherapy regimen pre-treatment for CAR-T therapy with axicabtagene ciloleucel (Yescarta®) in adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy.</p>
</td>
</tr>
<tr>
<td style="width: 442px;">
<p><strong>Fludarabine &amp; Cyclophosphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) DLBCL</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/car-t-therapy/606 .pdf">Regimen</a></strong></p>
</td>
<td style="width: 368px;">
<p><strong>00606a</strong></p>
<p>Lymphodepletion chemotherapy regimen pre-treatment for CAR-T therapy Tisagenlecleucel (Kymriah®) in adult patients with relapsed or refractory DLBCL after two or more lines of systemic therapy<strong></strong></p>
</td>
</tr>
<tr>
<td style="width: 442px;">
<p><strong>Fludarabine &amp; Cyclophosphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) B-cell ALL</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/car-t-therapy/607.pdf">Regimen</a></strong></p>
</td>
<td style="width: 368px;">
<p><strong>00607a</strong></p>
<p>Lymphodepleting chemotherapy regimen pre-treatment for CAR-T therapy Tisagenlecleucel (Kymriah®) in adult patients aged 18-25 years with B-cell ALL that is refractory, in relapse post-transplant or in second or later relapse<strong></strong></p>
</td>
</tr>
<tr>
<td style="width: 442px;"></td>
<td style="width: 368px;"></td>
</tr>
<tr>
<td style="width: 442px;">
<p><strong>Tisagenlecleucel (Kymriah®) (CAR-T) DLBCL</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/car-t-therapy/687.pdf">Regimen</a></strong></p>
</td>
<td style="width: 368px;">
<p><strong>00687a</strong></p>
<p>Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy</p>
</td>
</tr>
<tr>
<td style="width: 442px;">
<p><strong>Tisagenlecleucel (Kymriah®) (CAR-T) B-ALL</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/car-t-therapy/686.pdf">Regimen</a></strong></p>
</td>
<td style="width: 368px;">
<p><strong>00686a</strong></p>
<p>Treatment of young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse</p>
</td>
</tr>
<tr>
<td style="width: 442px;"></td>
<td style="width: 368px;"></td>
</tr>
</tbody>
</table><table border="1" cellpadding="1" cellspacing="2" class="null" summary="list of protocols">
<thead>
<tr align="left" valign="top">
<th id="th08254B500000"><strong>Regimen Name</strong></th>
<th id="th08254B500001"><strong>Indication</strong></th>
</tr>
</thead>
<tbody>
<tr align="left" valign="top">
<td>
<p><strong>Aflibercept and FOLFIRI Therapy -14 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/238-aflibercept-and-folfiri-therapy-14-days.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00238a</strong></p>
<p>Aflibercept is indicated as second line therapy in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy in adults with metastatic colorectal cancer (mCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Bevacizumab 10 mg/kg –14 days</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/212.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00212a</strong></p>
<p>In combination with fluoropyrimidine-based chemotherapy for treatment of adult patients with metastatic carcinoma of the colon or rectum.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Bevacizumab 7.5 mg/kg –21 days</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/214.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00214a</strong></p>
<p>In combination with fluoropyrimidine-based chemotherapy for treatment of adult patients with metastatic carcinoma of the colon or rectum.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Bevacizumab 15 mg/kg –21 days</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/215-bevacizumab-15mg-kg-therapy.pdf">Regimen</a></strong><strong></strong></p>
</td>
<td>
<p><strong>00215d</strong></p>
<p>In combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong><strong>Bevacizumab 5mg/kg and FOLFIRI Therapy-14 day</strong></strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/449.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00449a</strong></p>
<p>Treatment of adult patients with metastatic carcinoma of the colon or rectum.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong><strong><strong>Bevacizumab 5mg/kg and modified FOLFOX-6 Therapy-14 day</strong></strong></strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/446.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00446a</strong></p>
<p>Treatment of adult patients with metastatic carcinoma of the colon or rectum.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Bevacizumab 5mg/kg and FOLFOXIRI -14 day </strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/783-bevacizumab-and-folfoxiri.pdf">Regimen</a></p>
</td>
<td>
<p> <strong>00783a</strong></p>
<p>Treatment of metastatic colorectal cancer</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong><strong><strong>Bevacizumab 7.5mg/kg and Capecitabine 1250mg/m2 <br/> Therapy- 21 day</strong></strong></strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/00623a.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00623a</strong></p>
<p>Treatment of metastatic or unresectable colorectal cancer in patients not suitable for combination chemotherapy with irinotecan or oxaliplatin.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Capecitabine Monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/216-capecitabine-monotherapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00216b</strong></p>
<p>Treatment of metastatic colorectal cancer.</p>
<p><strong>00216c</strong></p>
<p>Adjuvant treatment of patients following surgery of stage III colon cancer.</p>
<p><strong>00216d*</strong></p>
<p>Adjuvant treatment of patients following surgery of stage II colon cancer.</p>
<p><strong>00216e*</strong></p>
<p>Adjuvant treatment of patients with metastatic colorectal cancer following complete resection.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Capecitabine 825mg/m<sup>2</sup> and RT–7 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/586-capecitabine-825mg-m2-and-rt%E2%80%937-day.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00586a</strong></p>
<p>Locally advanced rectal cancer</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Capecitabine and RT–7 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/523-capecitabine-and-rt%E2%80%937-day.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00523a</strong></p>
<p>Locally advanced pancreatic cancer after induction chemotherapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Capecitabine and Temozolomide Therapy*</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/505.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00505a</strong></p>
<p>Treatment of patients with locally advanced or metastatic neuroendocrine tumours of the pancreas.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Capecitabine/Oxaliplatin (XELOX) Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/321.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00321a</strong></p>
<p>Adjuvant treatment of stage III (Dukes C) colon cancer after complete resection of the primary tumour.</p>
<p><strong>00321b</strong></p>
<p>Treatment of advanced or metastatic colorectal cancer.</p>
<p><strong>00321c</strong></p>
<p>Adjuvant Stage II/III gastric adenocarcinoma post D2 gastrectomy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CARBOplatin (AUC 2) Weekly and PACLitaxel (50mg/m<sup>2</sup>) Weekly with Radiotherapy (RT) -5 weeks</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/422.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00422a</strong></p>
<p>Preoperative chemoradiation treatment of oesophageal and gastro-oesophageal junction carcinomas.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Cetuximab Therapy- 7 days</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/207.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00207a</strong></p>
<p>Treatment of patients with epidermal growth factor receptor (EGFR)-expressing RAS wild-type metastatic colorectal cancer (mCRC)</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Cetuximab Therapy- 14 days*</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/732-cetuximab-therapy-14-days.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00732a</strong></p>
<p>As monotherapy for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing RAS wild-type metastatic colorectal cancer (mCRC) in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Cetuximab (7days) and Irinotecan (14 days ) Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/330-cetuximab-7days-and-irinotecan-14-days-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00330a</strong></p>
<p>Second line therapy for metastatic colorectal cancer with non-mutated (wild type) <em>RAS </em>after failure of or contraindication to oxaliplatin based therapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Cetuximab (14 days) and Irinotecan (14 days ) Therapy*</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/331-cetuximab-14-days-and-irinotecan-14-days-therapy-.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00331a</strong></p>
<p>Second line therapy for metastatic colorectal cancer with non-mutated (wild type) <em>RAS </em>after failure of or contraindication to oxaliplatin based therapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Cetuximab and FOLFOX-4 Therapy </strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/692-cetuximab-and-folfox4.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00692a</strong></p>
<p>Treatment of patients with RAS wild type metastatic colorectal cancer</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Cetuximab (14 days) and FOLFIRI (14 days) Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/585.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00585a</strong></p>
<p>Treatment of patients with RAS wild type metastatic colorectal cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Cetuximab and FOLFOX-6 (modified) Therapy*</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/733-cetuximab-and-folfox-6-modified-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00733a</strong></p>
<p>Treatment of patients with KRAS wild type metastatic colorectal cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CISplatin and Capecitabine Adjuvant Chemoradiation Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/473.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00473a</strong></p>
<p>Adjuvant treatment of adult patients with resected gastric cancer stage IIA or higher and no distant metastases.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CISplatin 75mg/m<sup>2</sup> and 5-Fluorouracil Chemoradiation Therapy-Herskovic Regimen</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/460.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00460a</strong></p>
<p>Locally advanced squamous or adenocarcinoma of the oesophagus not suitable for surgery.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CISplatin, 5-Fluorouracil and Radiation Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/594.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00594a</strong></p>
<p>Treatment of anal canal carcinoma.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CISplatin and Teysuno<sup>®</sup>-28 day cycle</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/235-cisplatin-and-teysuno%C2%AE-28-day-cycle.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00235a</strong></p>
<p>Treatment of advanced gastric cancer when given in combination with cisplatin.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>DOCEtaxel Monotherapy 75mg/m<sup>2</sup> – 21 day cycle</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/203.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00203d</strong></p>
<p>Advanced or metastatic adenocarcinoma of the stomach or gastro-oesophageal junction in patients who have progressed during or within 6 months after treatment with a platinum-fluoropyrimidine combination.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>DOXOrubicin 60mg/m<sup>2</sup> Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/386.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00386a</strong></p>
<p>Treatment of unresectable or metastatic hepatocellular carcinoma not suitable for treatment with regional therapies.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>epiRUBicin, CISplatin and 5-FU (ECF) Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/240-epirubicin-cisplatin-and-5-fu-ecf-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00240a</strong></p>
<p>Metastatic or locally advanced (unresectable) gastric adenocarcinoma.</p>
<p><strong>00240b</strong></p>
<p>Metastatic or locally advanced (unresectable) esophagogastric junction adenocarcinoma.</p>
<p><strong>00240c</strong></p>
<p>Metastatic or locally advanced (unresectable) oesophageal  adenocarcinoma.</p>
<p><strong>00240d</strong></p>
<p>Perioperative treatment of resectable gastric adenocarcinoma.</p>
<p><strong>00240e</strong></p>
<p>Perioperative treatment of resectable gastroesophageal junction adenocarcinoma.</p>
<p><strong>00240f</strong></p>
<p>Perioperative treatment of resectable lower oesophagus adenocarcinoma.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>epiRUBicin, CISplatin and Capecitabine (ECX) Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/380.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00380a</strong>&gt;</p>
<p>Perioperative treatment of resectable gastric adenocarcinoma.</p>
<p><strong>00380b</strong></p>
<p>Perioperative treatment of resectable gastrioesophageal junction adenocarcainoma.</p>
<p><strong>00380c</strong></p>
<p>Perioperative treatment of resectable lower oesophagus adenocarcinoma.</p>
<p><strong>00380d</strong></p>
<p>Palliative therapy for metastatic or locally advanced gastric adenocarcinoma.</p>
<p><strong>00380e</strong></p>
<p>Palliative therapy for metastatic or locally advanced oesphagogastric adenoccarcinoma.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>epiRUBicin Oxaliplatin and 5-FU (EOF) -21 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/429.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00429a</strong></p>
<p>Locally advanced or metastatic gastric carcinoma</p>
<p><strong>00429b</strong></p>
<p>Locally advanced or metastatic oesophageal carcinoma</p>
<p><strong>00429c</strong></p>
<p>Locally advanced or metastatic gastroesophageal carcinoma</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>epiRUBicin, Oxaliplatin and Capecitabine (EOX)Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/239.pdf"><strong>Regimen</strong></a></p>
</td>
<td>
<p><strong>00239a</strong></p>
<p>Locally advanced or metastatic gastric carcinoma.</p>
<p><strong>00239b</strong></p>
<p>Locally advanced or metastatic oesophageal carcinoma.</p>
<p><strong>00239c</strong></p>
<p>Locally advanced or metastatic gastroesophageal carcinoma.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Everolimus Monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/320-everolimus-monotherapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00320b</strong></p>
<p>Treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease.</p>
<p><strong>00320c</strong></p>
<p>The treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal origin in adults with progressive disease</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>FLOT Therapy-14 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/344.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00344a</strong></p>
<p>Treatment of locally advanced (≥T2) and/or nodal positive (N+) resectable gastric adenocarcinoma</p>
<p><strong>00344b</strong></p>
<p>Treatment of locally advanced ((≥T2) and/or nodal positive (N+) resectable adenocarcinoma of the oesophagogastreal junction</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>FLOX Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/486.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00486a</strong></p>
<p>Adjuvant treatment of stage II or III colon cancer after complete resection of primary tumour </p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>FOLFIRI Therapy-14 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/227-folfiri-therapy-14-day.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00227a</strong></p>
<p>Treatment of patients with advanced colorectal cancer.</p>
<p><strong>00227b</strong></p>
<p>Treatment of patients with metastatic oesophageal carcinoma.</p>
<p><strong>00227c</strong></p>
<p>Second line treatment of patients with locally advanced metastatic pancreatic carcinoma</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>FOLFIRI (14 days) and cetuximab (7 days) therapy </strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/328.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00328a</strong></p>
<p>Treatment of patients with RAS wild type metastatic colorectal cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>FOLFOX- 4 Therapy-14 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/210.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00210a</strong></p>
<p>Adjuvant treatment of stage II and stage III colon cancer after complete resection of primary tumour.</p>
<p><strong>00210b</strong></p>
<p>Metastatic colorectal carcinoma</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>FOLFOX- 6 Modified Therapy-14 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/209.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00209a</strong></p>
<p>Adjuvant treatment of stage II or III colon cancer after complete resection of primary tumour</p>
<p><strong>00209b</strong></p>
<p>Metastatic colorectal carcinoma</p>
<p><strong>00209c </strong></p>
<p>Advanced or metastatic adenocarcinoma of the stomach or gastro-oesophageal junction</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>FOLFOX-6 Modified Chemoradiation Therapy-14 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/509.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00509a</strong></p>
<p>Definitive squamous cell carcinoma (SCC) or adenocarcinoma of the oesophagus in combination in patients for whom a CISplatin based regimen is contraindicated.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>FOLFOXIRI Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/555.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00555a</strong></p>
<p>Treatment of  metastatic colorectal cancer</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>FOLFIRINOX</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/329.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00329a</strong></p>
<p>Metastatic pancreatic cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Modified FOLFIRINOX Therapy</strong></p>
<p><strong></strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/515.pdf"><strong>Regimen</strong></a><br/>     </p>
</td>
<td>
<p><strong>00515a</strong></p>
<p>Adjuvant treatment of pancreatic ductal adenocarcinoma</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>FOLFIRINOX Therapy - (Rectal Carcinoma)</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/folfirinox-rectal-carcinoma-v1-691.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong><strong>00691a</strong></strong></p>
<p>Neoadjuvant chemotherapy for locally advanced rectal cancer</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>5-Fluorouracil and Folinic Acid Therapy-14 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/660-5-fu-and-folinic-acid-therapy-14-day.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00660a</strong></p>
<p>Adjuvant treatment of colorectal carcinoma</p>
<p><strong>00660b</strong></p>
<p>Locally advanced, locally recurrent or metastatic colorectal adenocarcinoma not curable with surgery or radiation</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>5-Fluorouracil (4 day) and mitoMYcin Chemoradiation Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/451-5-fluorouracil-4-day-and-mitomycin-chemoradiation-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00451a</strong></p>
<p>Treatment of anal canal carcinoma. </p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>5-fluorouracil  225mg/m<sup>2</sup>/day and Radiotherapy (RT)-Continuous infusion (7day)</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/421 5-fu.pdf"><strong>Regimen</strong></a></p>
</td>
<td>
<p><strong>00421a</strong></p>
<p>Treatment of locally advanced rectal cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Gemcitabine 1000mg/m<sup>2 </sup>Monotherapy-28 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/284-gemcitabine-1000mg-m2-monotherapy-28-day.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00284a</strong></p>
<p>Adjuvant chemotherapy for pancreatic adenocarcinoma.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Gemcitabine 1000mg/m<sup>2 </sup>Monotherapy- 56 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/283.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00283a</strong></p>
<p>Treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Gemcitabine (400mg/m<sup>2</sup>) and RT therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/522-gemcitabine-400mg-m2-and-rt-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00522a</strong></p>
<p>Resectable Adenocarcinoma of the head of Pancreas.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Gemcitabine (600mg/m<sup>2</sup>) and RT Therapy – 7day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/gemcitabine-600mg-m2-and-rt-therapy-%E2%80%93-7day.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00559a</strong></p>
<p>Treatment of patients with localized unresectable adenocarcinoma of the pancreas.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Gemcitabine (1000mg/m<sup>2</sup>) and RT therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/521-gemcitabine-1000mg-m2-and-rt-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00521a</strong></p>
<p>Non-metastatic, locally advanced pancreatic cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong> Gemcitabine (1000mg/m<sup>2</sup>) and Capecitabine (650mg/m<sup>2</sup>) Therapy- 21 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/384-gemcitabine-1000mg-m2-and-capecitabine-650mg-m2-therapy-21-day.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00384a</strong></p>
<p>Locally advanced or metastatic pancreatic carcinoma.</p>
<p><strong>00384b</strong></p>
<p>Locally advanced biliary tree carcinoma.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Gemcitabine (1000mg/m<sup>2</sup>) and Capecitabine (830mg/m<sup>2</sup>) Therapy- 28 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/524.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00524a</strong></p>
<p>Adjuvant treatment of pancreatic adenocarcinoma after macroscopic complete resection.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Gemcitabine (1000mg/m<sup>2</sup>) and CISplatin (25mg/m<sup>2</sup>)Therapy-21 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/383-gemcitabine-1000mg-m2-and-cisplatin-25mg-m2-therapy-21-day.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00383a</strong></p>
<p>Locally advanced or metastatic pancreatic carcinoma</p>
<p><strong>00383b</strong></p>
<p>Locally advanced or metastatic biliary tree carcinoma.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Irinotecan Monotherapy - 21days</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/213-irinotecan-monotherapy-21days.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00213a</strong></p>
<p>Treatment of patients with advanced colorectal cancer as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Irinotecan 150mg/m2 Monotherapy – 28 days</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/654.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00654a</strong></p>
<p>Second line therapy for advanced gastric cancer refractory to treatment with fluoropyrimidine plus platinum.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Lenvatinib_HCC Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/644-lenvatinib-hcc-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00644a</strong></p>
<p>As monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>mitoMYcin and Capecitabine Chemoradiation Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/727-mitomycin-and-capecitabine-chemoradiation-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00727</strong></p>
<p>Treatment of anal canal carcinoma</p>
</td>
</tr>
<tr align="left" valign="top">
<td class="null">
<p><strong>nab-PACLitaxel and Gemcitabine -28 Days</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/256.pdf">Regimen</a></strong></p>
</td>
<td class="null">
<p><strong>00256a</strong></p>
<p>First-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.</p>
</td>
</tr>
<tr align="left" valign="top">
<td class="null">
<p><strong>PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/621.pdf">Regimen</a></p>
</td>
<td class="null">
<p><strong>00621a</strong></p>
<p>Second line chemotherapy for advanced or recurrent gastric cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Panitumumab 6mg/kg Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/225.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00225c</strong></p>
<p>Treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) As monotherapy after failure of fluorpyridine, oxaliplatin, and irinotecan containing chemotherapy regimens</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Panitumumab 6mg/kg and FOLFIRI Therapy-14 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/448 panitumumab-6mg-kg-and-folfiri-therapy-14-day.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00448a</strong></p>
<p>First line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC)</p>
<p><strong>00448b</strong></p>
<p>Second line treatment of adult patients with wild-type RAS mCRC who have received first-line fluorpyridine–based chemotherapy (excluding irinotecan)</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Panitumumab 6mg/kg and modified FOLFOX-6  Therapy-14 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/447.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00447a</strong></p>
<p>First line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC)</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>QUASAR (Modified) Flu Fluorouracil (370mg/m<sup>2</sup>) and<br/>Folinic Acid (50mg) weekly</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/428-qqquasar-modified-flu-fluorouracil-370mg-m2-and-3-and-folinic-acid-50mg-weekly.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00428a</strong></p>
<p>Treatment of metastatic colorectal cancer.</p>
<p><strong>00428b</strong></p>
<p>Adjuvant treatment of colorectal cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Regorafenib Monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/244.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00244a</strong></p>
<p>Treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Roswell Park Modified (Fluorouracil 500mg/m<sup>2</sup> and Folinic Acid 50mg weekly x 6) Regimen</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/427.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00427a</strong></p>
<p>Treatment of metastatic colorectal cancer.</p>
<p><strong>00427b</strong></p>
<p>Adjuvant treatment of colorectal cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>SORAfenib Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/294-sorafenib-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00294a</strong></p>
<p>Treatment of hepatocellular carcinoma (HCC).</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Trastuzumab 5 Fluorouracil and CISplatin Therapy-21days</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/502trastuzumab-5-fluorouracil-and-cisplatin-therapy-21.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00502a</strong></p>
<p>Treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Trastuzumab and FOLFOX-6 Modified Therapy-14 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/trastuzumab-with-folfox6-modified-v1-final.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00704a</strong></p>
<p>Treatment of adult patients with HER2 positive metastatic gastric or gastroesophageal junction cancer</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Trifluridine and Tipracil (Lonsurf<sup>®</sup>)Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/382.pdf"><strong>Regimen</strong></a></p>
</td>
<td>
<p><strong>00382a</strong></p>
<p>Treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.</p>
</td>
</tr>
</tbody>
</table><table border="1" cellpadding="1" cellspacing="2" height="1095" summary="list of renal protocols">
<caption>
<p><strong>Bladder Cancer Chemotherapy Regimens</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/pd-l1-ihc-request-form-urothelial-carcinoma.docx">PD-L1 IHC request Form Urothelial Cancer</a></p>
</caption>
<tbody>
<tr align="left" valign="top">
<td><strong>Regimen Name</strong></td>
<td><strong>Indication</strong></td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Atezolizumab 1200mg Monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/544-atezolizumab-1200mg-monotherapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00544b</strong></p>
<p>Treatment of adult patients with locally advanced or metastatic<br/>urothelial carcinoma (UC) after prior platinum-containing<br/>chemotherapy.</p>
<p><strong>00544c</strong></p>
<p>Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible and whose tumours have a PD-L1 expression ≥5%</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p> <strong>Atezolizumab 1680mg Monotherapy – 28 Day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/593-atezolizumab-1680mg-monotherapy-28-day.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00593b</strong></p>
<p>Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) after prior platinum-containing chemotherapy.</p>
<p><strong>00593c</strong></p>
<p>Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible and whose tumours have a PD-L1 expression ≥5%.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Avelumab Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/535-avelumab-monotherapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00535</strong></p>
<p>First-line maintenance treatment of adult patients with locally advancedor metastatic urothelial carcinoma (UC) who are progression-free following platinum based chemotherapy</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CISplatin 40mg/m2 Weekly with Radiotherapy (RT)</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/385-cisplatin-40mg-m2-weekly-with-radiotherapy-rt-.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00385b</strong></p>
<p>Chemoradiation treatment for locally advanced bladder cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Cisplatin, Methotrexate and Vinblastine (CMV) Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/337-cisplatin-methotrexate-and-vinblastine-cmv-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00337a</strong></p>
<p>Neoadjuvant treatment of muscle invasive transitional cell carcinoma (TCC) of the urothelium.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>5-Fluorouracil (5 day) and mitoMYcin Chemoradiation Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/450-5-fluorouracil-5-day-and-mitomycin-chemoradiation-therapy.pdf"><strong>Regimen </strong></a></p>
</td>
<td>
<p><strong>00450a</strong></p>
<p>Treatment of muscle invasive bladder cancer in patients.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Gemcitabine (1000mg/m2) and CISplatin (35mg/m2) <br/> Therapy- 21 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/622.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00622a</strong></p>
<p>Treatment of patients with locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium in patients with impaired renal function.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Gemcitabine (1000mg/m2) and CISplatin (70mg/m2) </strong><br/><strong> Therapy- 21 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/628.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00628a</strong></p>
<p>Adjuvant treatment of upper tract urothelial carcinoma.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Gemcitabine (1000mg/m<sup>2</sup>) and CARBOplatin (AUC5) Therapy-21 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/310.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00310a</strong></p>
<p>Treatment of patients with locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium where cisplatin is contraindicated.*</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Gemcitabine (1000mg/m<sup>2</sup>) and CISplatin (70mg/m<sup>2</sup>) Therapy-28 day </strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/282-gemcitabine-1000mg-m2-and-cisplatin-70mg-m2-therapy-28-day.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00282a</strong></p>
<p>Treatment of patients with locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Methotrexate, VinBLAStine, DOXOrubicin, CISplatin (MVAC) Therapy-14 days </strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/333-methotrexate-vinblastine-doxorubicin-cisplatin-mvac-therapy-14-days.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00333a</strong></p>
<p>Locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Methotrexate, vinBLAStine, DOXOrubicin, CISplatin (MVAC) Therapy-28 days </strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/338-methotrexate-vinblastine-doxorubicin-cisplatin-mvac-therapy-28-days.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00338a</strong></p>
<p>Neoadjuvant treatment of muscle invasive transitional cell carcinoma (TCC) of the urothelium.</p>
<p><strong>00338b</strong></p>
<p>Adjuvant treatment of muscle invasive TCC of the urothelium.</p>
<p><strong>00338c</strong></p>
<p>Locally advanced or metastatic TCC of the urothelium.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/226-paclitaxel-monotherapy-80mg-m2-7day-cycle.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00226e</strong></p>
<p>Second line chemotherapy for metastatic bladder cancer<sup>ii</sup>.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/621.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00621e</strong></p>
<p>Second line chemotherapy for metastatic bladder cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Pembrolizumab 200mg Monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/pembrolizumab 200mg monotherapy 455 .pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00455e</strong></p>
<p>As monotherapy for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy.</p>
<p><strong>00455f</strong></p>
<p>As monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy whose tumours express PD-L1 with a combined positive score (CPS) ≥10.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Pembrolizumab 400mg Monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/558-pembrolizumab-400-mg-monotherapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00558e</strong></p>
<p>As monotherapy for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy.</p>
<p><strong>00558f</strong></p>
<p>As monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy whose tumours express PD-L1 with a combined positive score (CPS) ≥10.</p>
</td>
</tr>
</tbody>
</table><table border="1" cellpadding="1" cellspacing="2" height="505" summary="list of renal protocols">
<caption>
<p><strong>Germ Cell Chemotherapy Regimens</strong></p>
</caption>
<thead>
<tr align="left" valign="top">
<th id="th068AEBF80000"><strong>Regimen</strong> Name</th>
<th id="th068AEBF80001">Indication</th>
</tr>
</thead>
<tbody>
<tr align="left" valign="top">
<td>
<p><strong>Bleomycin, Etoposide and CISplatin (BEP) Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/300-bleomycin-etoposide-and-cisplatin-bep-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00300a</strong></p>
<p>Adjuvant treatment of high risk (vascular invasion carcinoma) stage 1 nonseminoma germ cell tumour.</p>
<p><strong>00300b</strong></p>
<p>Metastatic germ cell tumours of the testis.</p>
<p><strong>00300c</strong></p>
<p>Advanced stage or metastatic germ cell tumours (dysgermimoma) of the ovaries.</p>
<p><strong>00300d</strong></p>
<p>Extra-gonadal germ cell tumours.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CARBOplatin (AUC7) and Etoposide- Autologous Conditioning Germ Cell Tumour Regimen</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/453-carboplatin-auc7-and-etoposide-autologous-conditioning-germ-cell-tumour-regimen.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00453a</strong></p>
<p>Treatment of metastatic relapsed/refractory germ cell tumours.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Etoposide and CISplatin 20mg/m<sup>2</sup> (EP) 5 Day Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/301-etoposide-and-cisplatin-20mg-m2-ep-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00301a</strong></p>
<p>Treatment of good prognosis (IGCCCG criteria) metastatic germ cell tumours (both non-seminoma and seminoma).</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>TICE - Autologous Conditioning Germ Cell Tumour Regimen</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/437-tice-autologous-conditioning-germ-cell-tumour-regimen.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00437a</strong></p>
<p>Treatment of metastatic relapsed/refractory germ cell tumours.</p>
</td>
</tr>
</tbody>
</table><table border="1" cellpadding="1" cellspacing="2" height="890" summary="list of protocols">
<caption>
<p><strong>Prostate Chemotherapy Regimens</strong></p>
</caption>
<thead>
<tr align="left" valign="top">
<th id="th063BFFC00000"><strong><strong>Regimen</strong> Name</strong></th>
<th id="th063BFFC00001"><strong>Indication</strong></th>
</tr>
</thead>
<tbody>
<tr align="left" valign="top">
<td>
<p><strong>Abiraterone and Prednisolone Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/103-abiraterone-and-prednisolone-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00103a</strong></p>
<p>Treatment of mCRPC which has progressed on or after a docetaxel-based chemotherapy regimen.</p>
<p><strong>00103b</strong></p>
<p>Treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Abiraterone 1000mg and Prednisolone 5mg Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/577.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00577a</strong></p>
<p>Abiraterone is indicated with prednisone or prednisolone for: the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Apalutamide Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/574.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00574a</strong></p>
<p>Apalutamide is indicated for the treatment of adult men with nonmetastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Bicalutamide Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/482-bicalutamide-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00482</strong></p>
<p>Treatment of advanced prostate cancer in combination with luteinizing-hormone releasing hormone (LHRH) analogue therapy or surgical castration.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Cabazitaxel and Prednisolone</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/cabazitaxelprotocol.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00101a</strong></p>
<p>Cabazitaxel is indicated in combination with prednisone or prednisolone for the treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Darolutamide Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/693.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00693a</strong></p>
<p>Treatment of adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Degarelix Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/481-degarelix-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00481a</strong></p>
<p>Treatment of adult male patients with advanced hormone-dependent prostate cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Denosumab 120mg Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/741-denosumab120mg_v1.pdf"><strong></strong></a><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/741-densosumab-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00741a</strong></p>
<p>For the prevention of skeletal related events in adult patients with malignancies involving bone.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Docetaxel Monotherapy 50mg/m<sup>2</sup> – 14 day cycle</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/313-docetaxel-monotherapy-50mg-m2-%E2%80%93-14-day-cycle.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00313a</strong></p>
<p>In combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>DOCEtaxel Monotherapy 75mg/m<sup>2</sup> - 21 day cycle</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/203.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00203b</strong></p>
<p>First line in high risk non metastic castration sensitive prostate cancer.</p>
<p><strong>00203c</strong></p>
<p>First line in metastatic castration sensitive prostate cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>DOCEtaxel 75 mg/m<sup>2</sup> – Prednisolone Combination Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/546-docetaxel-75mg-m2-%E2%80%93prednisolone-combination-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00546a</strong></p>
<p>In combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Enzalutamide Monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/233-enzalutamide-monotherapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00233a</strong></p>
<p>Treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.</p>
<p><strong>00233b<br/></strong>Treatment of adult men with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.</p>
<p><strong>00233c</strong></p>
<p>The treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Goserelin 3.6mg Therapy -28 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/478-goserelin-3-6mg-therapy-28-day.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00478a</strong></p>
<p>Treatment of locally advanced or metastatic hormone sensitive prostate cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Goserelin 10.8mg Therapy -12week</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/477-goserelin-10-8mg-therapy-12week.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00477a</strong></p>
<p>Treatment of locally advanced or metastatic hormone sensitive prostate cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Leuprorelin 3.75mg Therapy-28 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/494-leuprorelin-3-75mg-therapy-28-day.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00494a</strong></p>
<p>Management of prostatic carcinoma for which a suppression of testosterone is indicated.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Leuprorelin 7.5mg Therapy-28 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/490-leuprorelin-7-5mg-therapy-28-day.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00490a</strong></p>
<p>Treatment of hormone dependent advanced prostate cancer. </p>
<p><strong>00490b </strong></p>
<p>Treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Leuprorelin 11.25mg Therapy-12 week</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/492-leuprorelin-11-25mg-therapy-12-week.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00492a</strong></p>
<p>Management of prostatic carcinoma for which a suppression of testosterone is indicated.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Leuprorelin 22.5mg Therapy-12 week</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/479-leuprorelin-22-5mg-therapy-12-week.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00479a</strong></p>
<p>Treatment of hormone dependent advanced prostate cancer.</p>
<p><strong>00479b </strong></p>
<p>Treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Leuprorelin 30mg-24 week</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/493-leuprorelin-30mg-24-week.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00493a</strong></p>
<p>Treatment of locally advanced or metastatic hormone dependent advanced prostate cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Leuprorelin 45mg Therapy-24 week</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/491-leuprorelin-45mg-therapy-24-week.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00491a </strong></p>
<p>Treatment of hormone dependent advanced prostate cancer. </p>
<p><strong>00491b</strong></p>
<p>Treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Radium 223 Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/257-radium-223-therapy1.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00257a</strong></p>
<p>As monotherapy or in combination with LHRH analogues for the treatment of adults with progressive castration-resistant metastatic prostate cancer (mCRPC, symptomatic bone metastases and no extensive visceral metastases after at least two prior lines of systemic therapy for mCRPC (other than LHRH analogues), or ineligible for any available licensed systemic mCRPC treatment.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Triptorelin 3mg Therapy-28 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/489-triptorelin-3mg-therapy-28-day.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00489a </strong></p>
<p>Treatment of locally advanced or metastatic hormone dependent advanced prostate cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Triptorelin 11.25mg Therapy-12 week</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/480-triptorelin-11-25mg-therapy-12-week.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00480a</strong></p>
<p>Treatment of locally advanced or metastatic hormone dependent advanced prostate cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Triptorelin 22.5mg Therapy-24 week</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/488-triptorelin-22-6mg-therapy-24-week.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00488a</strong></p>
<p>Treatment of locally advanced or metastatic hormone dependent advanced prostate cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Zoledronic Acid Therapy-28 days</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/zoledronic-acid-28days-v1-723.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00723a</strong></p>
<p>Prevention of skeletal related events in malignancies involving bone metastases</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Zoledronic Acid Therapy-3 monthly</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/zoledronic-acid-3-monthly-v1-724.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00724a</strong></p>
<p>Prevention of skeletal related events in malignancies involving bone metastases</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Zoledronic Acid Therapy-6 monthly</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/zoledronic-acid-6-monthly-v1-725.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00725a</strong></p>
<p>Prevention of skeletal related events in malignancies involving bone metastases</p>
</td>
</tr>
</tbody>
</table><table border="1" cellpadding="1" cellspacing="2" height="787" summary="list of renal protocols">
<caption>
<p><strong><strong>Renal Chemotherapy Regimen</strong>s</strong></p>
</caption>
<thead>
<tr align="left" valign="top">
<th id="th068AEBF80000"><strong><strong>Regimen</strong></strong> Name</th>
<th id="th068AEBF80001">Indication</th>
</tr>
</thead>
<tbody>
<tr align="left" valign="top">
<td>
<p><strong>Axitinib Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/axitinib104.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00104a</strong></p>
<p>Treatment of adult patients with advanced RCC after failure, on a previous line of therapy, i.e. treatment with SUNItinib, or a cytokine.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Atezolizumab 840mg Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/592-atezolizumab-840mg-monotherapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00592a</strong></p>
<p>Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy.</p>
<p><strong>00592b</strong></p>
<p>Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) after prior platinum-containing chemotherapy.</p>
<p><strong>00592c</strong></p>
<p>Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible and whose tumours have a PD-L1 expression ≥5%.<strong></strong></p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Bevacizumab 10 mg/kg –14 days</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/212.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00212d</strong></p>
<p>In combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Cabozantinib Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/518 cabozantinib therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00518a</strong></p>
<p>Treatment of advanced renal cell carcinoma (RCC) in adults following prior VEGF targeted therapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Everolimus Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/320-everolimus-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00320a</strong></p>
<p>Treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Pembrolizumab 200mg and Axitinib Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/583.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00583a</strong></p>
<p>Pembrolizumab in combination with axitinib for the first-line treatment of advanced renal cell carcinoma (RCC) in adults.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Nivolumab 240mg Monotherapy - 14 Days</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/483-nivolumab-240mg-monotherapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00483b</strong></p>
<p>As monotherapy for the treatment of advanced renal cell carcinoma (RCC) after prior therapy in adults.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Nivolumab 480mg Monotherapy -28 Days</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/484-nivolumab-480mg-monotherapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00484b </strong></p>
<p>As monotherapy for the treatment of advanced renal cell carcinoma (RCC) after prior therapy in adults.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Nivolumab 3mg/kg with Ipilimumab 1mg/kg Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/551-nivolumab-3mg-ipilimumab-1mg-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00551a</strong></p>
<p>Nivolumab in combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (RCC).</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>PAZOPanib Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/445-pazopanib-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00445a</strong></p>
<p>First line treatment of advanced Renal Cell Carcinoma (RCC) in adults and for patients who have received prior cytokine therapy for advanced disease.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>SORAfenib Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/294-sorafenib-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00294b</strong></p>
<p>Treatment of patients with advanced renal cell carcinoma (RCC) who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>SUNitinib 50mg Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/325-sunitnib-50mg-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00325b</strong></p>
<p>Treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>SUNitinib 50mg (21 Days) Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/sunitinib-50mg-therapy1.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00719b</strong></p>
<p>Treatment of clear-cell type metastatic renal cell carcinoma (MRCC).</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Temsirolimus Monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/326-temsirolimus-monotherapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00326a</strong></p>
<p>First-line treatment of adult patients with advanced renal cell carcinoma (RCC) who have at least three of six prognostic risk factors.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Tivozanib Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/564-tivozanib-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00564a</strong></p>
<p>Tivozanib for the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC.</p>
</td>
</tr>
</tbody>
</table><table border="1" cellpadding="1" cellspacing="2" class="null" height="180" summary="list of protocols" width="781">
<caption>Regimens</caption>
<thead>
<tr align="left" valign="top">
<th class="null" id="th09B5F4F00000"><strong><strong>Regimen</strong> Name</strong></th>
<th class="null" id="th09B5F4F00001"><strong>Indication</strong></th>
</tr>
</thead>
<tbody>
<tr align="left" valign="top">
<td class="null">
<p><strong>CARBOplatin (AUC 2) Weekly with Radiotherapy (RT)</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/419-carboplatin-auc-2-weekly-with-radiotherapy-rt-.pdf">Regimen</a></p>
</td>
<td class="null">
<p><strong>00419b</strong></p>
<p>Chemoradiation treatment in locally advanced cervical cancer when CISplatin is contraindicated or not tolerated.</p>
</td>
</tr>
<tr align="left" valign="top">
<td class="null">
<p><strong>CISplatin 40mg/m<sup>2</sup> Weekly with Radiotherapy (RT)</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/385-cisplatin-40mg-m2-weekly-with-radiotherapy-rt-.pdf">Regimen</a></p>
</td>
<td class="null">
<p><strong>00385a</strong></p>
<p>Chemoradiation treatment for locally advanced (stage IIB to IVA) cervical squamous cell carcinoma (SCC).</p>
</td>
</tr>
</tbody>
</table><table border="1" cellpadding="1" cellspacing="2" class="null" height="1319" summary="list of protocols" width="813">
<thead>
<tr align="left" valign="top">
<th class="null" id="th09B5F4F00000"><strong><strong>Regimen</strong> Name</strong></th>
<th class="null" id="th09B5F4F00001"><strong>Indication</strong></th>
</tr>
</thead>
<tbody>
<tr align="left" valign="top">
<td class="null">
<p><strong>DACTINomycin Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/247-dactinomycin-therapy.pdf">Regimen</a></p>
</td>
<td class="null">
<p><strong>00247a</strong></p>
<p>Alternative treatment of low risk gestational trophoblastic disease (GTD) (risk score ≤ 6)</p>
</td>
</tr>
<tr align="left" valign="top">
<td class="null">
<p><strong>EMA/CO Therapy (Etoposide, Methotrexate, DACTINomycin, Cyclophosphamide, vinCRIStine) </strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/248-ema-co-therapy-etoposide-methotrexate-dactinomycin-cyclophosphamide-vincristine-.pdf">Regimen</a></p>
</td>
<td class="null">
<p><strong>00248a</strong></p>
<p>Treatment of high risk gestational trophoblastic neoplasia (GTN) (FIGO score ≥7).</p>
<p><strong>00248b</strong></p>
<p>Treatment of patients with low risk GTN who have not responded or have relapsed from single agent chemotherapy (methotrexate or actinomycin D).</p>
</td>
</tr>
<tr align="left" valign="top">
<td class="null">
<p><strong>Two Day Etoposide CISplatin (EP) Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/267-two-day-etoposide-cisplatin-ep-therapy.pdf">Regimen</a></p>
</td>
<td class="null">
<p><strong>00267a</strong></p>
<p>Emergency treatment of women with Gestational Trophoblastic Neoplasia (GTN) who are acutely unwell from liver or CNS disease and particularly those at risk of respiratory failure.</p>
<p><strong>00267b</strong></p>
<p>Hepatic Metastases.<br/>Women with GTN who are acutely unwell from liver disease.</p>
<p><strong>00267c</strong></p>
<p>Cerebral Metastases.<br/>Women with GTN who are acutely unwell from cerebral metastases.</p>
</td>
</tr>
<tr align="left" valign="top">
<td class="null">
<p><strong>EMA/EP Therapy (Etoposide Methotrexate DACTINomycin/Etoposide CISplatin)</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/264-ep-ema-therapy-etoposide-cisplatin-etoposide-methotrexate-dactinomycin-.pdf">Regimen</a></p>
</td>
<td class="null">
<p><strong>00264a</strong></p>
<p>Treatment of women with high-risk Gestational Trophoblastic Neoplasia (GTN) who have not responded or have relapsed from treatment with EMA/CO.</p>
<p><strong>00264b</strong></p>
<p>GTN and hepatic metastases. Women with GTN and hepatic metastases at presentation.</p>
</td>
</tr>
<tr align="left" valign="top">
<td class="null">
<p><strong>Intrathecal Methotrexate for CNS prophylaxis in GTN</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/249-intrathecal-methotrexate-for-cns-prophylaxis-in-gtn.pdf">Regimen</a></p>
</td>
<td class="null">
<p><strong>00249a</strong></p>
<p>Central nervous system (CNS) prophylaxis in patients with high risk gestational trophoblastic neoplasia (GTN).</p>
<p><strong>00249b</strong></p>
<p>Central nervous system (CNS) prophylaxis in patients with low risk gestational trophoblastic neoplasia (GTN) with lung metastases.</p>
</td>
</tr>
<tr align="left" valign="top">
<td class="null">
<p><strong>Methotrexate 8 day Charing Cross Regimen</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/246-methotrexate-8-day-charing-cross-regimen.pdf">Regimen</a></p>
</td>
<td class="null">
<p><strong>00246a</strong></p>
<p>Treatment of low risk gestational trophoblastic disease (GTD) (FIGO score ≤ 6).</p>
</td>
</tr>
<tr align="left" valign="top">
<td class="null">
<p><strong>PACLitaxel/Etoposide alternating with PACLitaxel/CISplatin (TE/TP) Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/266-paclitaxel-cisplatin-alternating-with-paclitaxel-etoposide-tp-te-therapy.pdf">Regimen</a></p>
</td>
<td class="null">
<p><strong>00266a</strong></p>
<p>Treatment of women with high-risk Gestational Trophoblastic Neoplasia (GTN) who have not responded or have relapsed from treatment with EMA/CO.</p>
</td>
</tr>
</tbody>
</table><table border="1" cellpadding="1" cellspacing="2" class="null" summary="list of protocols" width="813">
<caption>
<p><strong>Ovarian Chemotherapy Regimens</strong></p>
</caption>
<tbody>
<tr align="left" valign="top">
<td>
<p><strong>Bleomycin, Etoposide and CISplatin (BEP) Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/300-bleomycin-etoposide-and-cisplatin-bep-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00300a</strong></p>
<p>Adjuvant treatment of high risk (vascular invasion carcinoma) stage 1 nonseminoma germ cell tumour.</p>
<p><strong>00300b</strong></p>
<p>Metastatic germ cell tumours of the testis.</p>
<p><strong>00300c</strong></p>
<p>Advanced stage or metastatic germ cell tumours (dysgermimoma) of the ovaries.</p>
<p><strong>00300d</strong></p>
<p>Extra-gonadal germ cell tumours.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Bevacizumab 10mg/kg Therapy-14 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/212.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00212b</strong></p>
<p>In combination with paclitaxel, topotecan (given weekly), or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer</p>
<p>who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Bevacizumab 15mg/kg, CARBOplatin (AUC 6) and PACLitaxel 175mg/m2 Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/766-bevacizumab-15mg-kg-carboplatin-auc-6-and-paclitaxel-175mg-m2-therapy.pdf">Regimen</a></p>
</td>
<td>
<p> <strong>00766a</strong></p>
<p>For the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Bevacizumab 15mg/kg Therapy-21 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/bevacizumab-15mg-kg-21-days.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00215a</strong></p>
<p>In combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.</p>
<p><strong>00215c</strong></p>
<p>In combination with, topotecan given on days 1-5 every 3 weeks*, for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Bevacizumab 10mg/kg and Pegylated liposomal DOXOrubicin (CAELYX®) 40mg/m2 Therapy </strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/bevacizumab-10mg-kg-and-pegylated-liposomal-doxorubicin-caelyx-40mg-m2-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00772a</strong></p>
<p>For the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents. </p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Bevacizumab 7.5mg/kg, CARBOplatin (AUC5) and PACLitaxel 175mg/m2 Therapy<sup>i</sup></strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/bev-7-5mg-kg-carbo-auc5-and-paclitaxel-175mg-m2-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00620a</strong></p>
<p>Bevacizumab in combination with CARBOplatin and PACLItaxel is indicated as first line post-surgical treatment in FIGO stage III after surgery with residual disease ≥1cm or FIGO stage IV epithelial ovarian, fallopian tube or primary peritoneal cancer</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Bevacizumab 10mg/kg and PACLitaxel 80mg/m2 (Day 1, 8, 15 and 22) Therapy  </strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/769-bevacizumab-10mg-kg-and-paclitaxel-80mg-m2-day-1-8-15-and-22-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00769</strong></p>
<p>For the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Bevacizumab 10mg/kg and Topotecan 4mg/m2 Therapy </strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/771-bevacizumab-10mg-kg-and-topotecan-4mg-m2-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00771</strong></p>
<p>For the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Bevacizumab 15mg Paclitaxel and CARBOplatin AUC 5</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/716-bevacizumab-15mg-paclitaxel-and-carboplatin-auc-5.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00716a</strong></p>
<p>Bevacizumab in combination with CARBOplatin and PACLitaxel for the treatment of persistent recurrent or metastatic cervical cancer, not amenable to curative surgery or radiation therapy</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Bevacizumab 15 PACLItaxel and CARBO AUC6</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/766-bevacizumab-15-paclitaxel-and-carbo-auc6.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00766a</strong></p>
<p>For the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CARBOplatin (AUC 4-6) Monotherapy- 28 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/251.pdf">Regimen</a></strong></p>
</td>
<td>
<p>First line adjuvant therapy of</p>
<p><strong>00251a</strong></p>
<p>ovarian carcinoma of epithelial origin</p>
<p><strong>00251b</strong></p>
<p>primary peritoneal carcinoma</p>
<p><strong>00251c</strong></p>
<p>fallopian tube cancer</p>
<p>where combination therapy is not suitable.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CARBOplatin (AUC 4-6) Monotherapy- 28 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/251.pdf">Regimen</a></p>
</td>
<td>
<p>First line therapy of advanced Stage 3 and 4</p>
<p><strong>00251d</strong></p>
<p>ovarian carcinoma of epithelial origin</p>
<p><strong>00251e</strong></p>
<p>primary peritoneal carcinoma</p>
<p><strong>00251f</strong></p>
<p>fallopian tube cancer</p>
<p>where surgery is not feasible and where combination therapy is not suitable.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CARBOplatin (AUC 4-6) Monotherapy- 28 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/251.pdf">Regimen</a></p>
</td>
<td>
<p>Treatment of recurrent, platinum-sensitive,</p>
<p><strong>00251g</strong></p>
<p>invasive ovarian carcinoma of epithelial origin</p>
<p><strong>00251h</strong></p>
<p>primary peritoneal carcinoma</p>
<p><strong>00251i</strong></p>
<p>fallopian tube cancer</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CARBOplatin (AUC 4-6) Monotherapy- 21 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/261.pdf">Regimen</a></p>
</td>
<td>
<p>First line adjuvant therapy of</p>
<p><strong>00261a</strong></p>
<p>ovarian carcinoma of epithelial origin</p>
<p><strong>00261b</strong></p>
<p>primary peritoneal carcinoma</p>
<p><strong>00261c</strong></p>
<p>fallopian tube cancer</p>
<p>where combination therapy is not suitable.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CARBOplatin (AUC 4-6) Monotherapy- 21 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/261.pdf">Regimen</a></p>
</td>
<td>
<p>First line therapy of advanced Stage 3 and 4</p>
<p><strong>00261d</strong></p>
<p>ovarian carcinoma of epithelial origin</p>
<p><strong>00261e</strong></p>
<p>primary peritoneal carcinoma</p>
<p><strong>00261f</strong></p>
<p>fallopian tube cancer</p>
<p>where surgery is not feasible and where combination therapy is not suitable.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CARBOplatin (AUC 4-6) Monotherapy- 21 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/261.pdf">Regimen</a></p>
</td>
<td>
<p>Treatment of recurrent, platinum-sensitive,</p>
<p><strong>00261g</strong></p>
<p>invasive ovarian carcinoma of epithelial origin</p>
<p><strong>00261h</strong></p>
<p>primary peritoneal carcinoma</p>
<p><strong>00261i</strong></p>
<p>fallopian tube cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CARBOplatin (AUC5-7.5) and PACLitaxel 175mg/m2 Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/303-carboplatin-auc5-7-5-and-paclitaxel-175mg-m2-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00303a</strong></p>
<p>Adjuvant treatment of high risk, stage I, epithelial ovarian cancer*</p>
<p><strong>00303b</strong></p>
<p>Treatment of advanced ovarian cancer</p>
<p><strong>00303c</strong></p>
<p>Treatment of primary peritoneal cancer</p>
<p><strong>00303d</strong></p>
<p>Treatment of fallopian tube cancer</p>
<p><strong>00303e</strong></p>
<p>Treatment of recurrent or advanced endometrial cancer (stage III or IV) *</p>
<p><strong>00303f</strong></p>
<p>Treatment of advanced/recurrent non small cell (NSC)cancer of the cervix<sup> *</sup></p>
<p><strong>00303g</strong></p>
<p>Treatment of carcinoma of unknown primary site<sup>*</sup></p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CARBOplatin (AUC 6) and Weekly PACLitaxel 80mg/m<sup>2</sup> Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/308-carboplatin-auc-5-6-and-weekly-paclitaxel-80mg-m2-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00308a</strong></p>
<p>Adjuvant treatment of high risk, stage I, epithelial ovarian cancer*</p>
<p><strong>00308b</strong></p>
<p>Treatment of advanced ovarian cancer*</p>
<p><strong>00308c</strong></p>
<p>Treatment of primary peritoneal cancer*</p>
<p><strong>00308d</strong></p>
<p>Treatment of fallopian tube cancer*</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Carboplatin AUC 5 and Pegylated Liposomal  <br/> DOXOrubicin 30mg/m2 Therapy-28 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/624.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00624a</strong></p>
<p>Treatment of patients with platinum sensitive relapsed/ recurrent ovarian cancer.</p>
<p><strong>00624b</strong></p>
<p>Treatment of patients with platinum sensitive relapsed/ recurrent primary peritoneal cancer.</p>
<p><strong>00624c</strong></p>
<p>Treatment of patients with platinum sensitive relapsed/ recurrent fallopian tube cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CISplatin (50mg/m2 ) Chemoradiation followed by CARBOplatin (AUC 5) and PACLitaxel (175mg/m2 ) – Endometrial Cancer</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/676.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00676a</strong></p>
<p>Adjuvant treatment for high risk, stage I (grade 3 with deep myometrial invasion and/or lymph-vascular invasion) stage II or III endometrial carcinoma or stage I–III endometrial carcinoma with serous or clear cell histology following surgery.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>DOCEtaxel Monotherapy 75mg/m<sup>2</sup> – 21 day cycle</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/203.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00203e</strong></p>
<p>Treatment of Relapsed/Progressing primary peritoneal<br/>carcinoma</p>
<p><strong>00203f</strong></p>
<p>Treatment of Relapsed/Progressing Epthelial Ovarian<br/>carcinoma</p>
<p><strong>00203g</strong></p>
<p>Treatment of Relapsed/Progressing Fallopian Tube<br/>Carcinoma</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Etoposide and CISplatin 20mg/m<sup>2</sup> (EP) 5 Day Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/301-etoposide-and-cisplatin-20mg-m2-ep-5-day-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00301a</strong></p>
<p>Treatment of good prognosis (IGCCCG criteria) metastatic germ cell tumours (both non-seminoma and seminoma).</p>
<p> </p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Gemcitabine 1000mg/m<sup>2 </sup>and CARBOplatin (AUC 4) Therapy-21 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/306.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00306a</strong></p>
<p>Treatment of patients with locally advanced or metastatic epithelial ovarian carcinoma, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first line therapy.</p>
<p><strong>00306b</strong></p>
<p>Treatment of patients with fallopian tube cancer with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first line therapy*</p>
<p><strong>00306c</strong></p>
<p>Treatment of patients with primary peritoneal cancer with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first line therapy<sup>*</sup></p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Gemcitabine(1000mg/m2),CARBOplatin (AUC 4) and Bevacizumab 15mg/kg  Therapy- 21 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/499.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00499a</strong></p>
<p>Treatment of adult patients with first recurrence of platinum-sensitive</p>
<p>epithelial ovarian,</p>
<p>fallopian tube or</p>
<p>primary peritoneal cancer</p>
<p>who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Niraparib Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/571-niraparib-monotherapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00571a</strong></p>
<p>As monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian cancer who are in response (complete or partial response) to platinum-based chemotherapy</p>
<p><strong>00571b</strong></p>
<p> As monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed fallopian tube  cancer who are in response (complete or partial response) to platinum-based chemotherapy</p>
<p><strong>00571c</strong></p>
<p>As monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed primary peritoneal  cancer who are in response (complete or partial response) to platinum-based chemotherapy</p>
</td>
</tr>
<tr align="left" valign="top">
<td> </td>
<td> </td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Olaparib (Tablets) Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00588a</strong></p>
<p>Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2‐mutated (germline and/or somatic) high-grade epithelial ovarian cancer who are in response (complete or partial) following completion of first‐line platinum based chemotherapy</p>
<p><strong>00588b</strong></p>
<p>Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2‐mutated (germline and/or somatic) fallopian tube cancer who are in response (complete or partial) following completion of first‐line platinum based chemotherapy</p>
<p><strong>00588c</strong></p>
<p>Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2‐mutated (germline and/or somatic) primary peritoneal carcinoma who are in response (complete or partial) following completion of first‐line platinum based chemotherapy</p>
<p><strong>00588d</strong></p>
<p>Maintenance treatment of adult patients with platinum -sensitive relapsed <em>BRCA</em>-mutated (germline and/or somatic) -high grade serous epithelial ovarian cancer who are in response (complete response or partial response) to platinum-based chemotherapy.</p>
<p><strong>00588e</strong></p>
<p>Maintenance treatment of adult patients with platinum -sensitive relapsed <em>BRCA</em>-mutated (germline and/or somatic) fallopian tube cancer who are in response (complete response or partial response) to platinum-based chemotherapy.</p>
<p><strong>00588f</strong></p>
<p>Maintenance treatment of adult patients with platinum -sensitive relapsed <em>BRCA</em>-mutated (germline and/or somatic) primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Pegylated Liposomal DOXOrubicin 50mg/m2(CAELYX) ® 28 days Regimen</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/205-pegylated-liposomal-doxorubicin-50mg-m2-caelyx-%C2%AE-28-days-regimen.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00205b</strong></p>
<p>Treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/226-paclitaxel-monotherapy-80mg-m2-7day-cycle.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00226b*</strong></p>
<p>Second-line chemotherapy for metastatic ovarian cancer after failure of standard, platinum-containing therapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/621.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00621c</strong></p>
<p>Second-line chemotherapy for metastatic ovarian cancer after failure of standard, platinum-containing therapy<sup>i</sup></p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Topotecan Monotherapy-5 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/311-topotecan-monotherapy-5-day.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00311a</strong></p>
<p>Treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy</p>
<p><strong>00311c</strong></p>
<p>Treatment of patients with metastatic carcinoma of the fallopian tubes after failure of first-line or subsequent therapy*</p>
<p><strong>00311d</strong></p>
<p>Treatment of patients with metastatic peritoneal  carcinoma after failure of first-line or subsequent therapy<strong><sup>*</sup></strong></p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Topotecan Monotherapy-Weekly*</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/312-topotecan-monotherapy-weekly-.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00312a</strong></p>
<p>Treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy</p>
<p><strong>00312b</strong></p>
<p>Treatment of patients with metastatic carcinoma of the fallopian tubes after failure of first-line or subsequent therapy</p>
<p><strong>00312c</strong></p>
<p>Treatment of patients with metastatic peritoneal  carcinoma after failure of first-line or subsequent therapy</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Trabectedin and Pegylated Liposomal DOXOrubicin (PLD) Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/375.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00375a</strong></p>
<p>Treatment of patients with relapsed platinum-sensitive ovarian cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Intravenous Vinorelbine Therapy-21 days</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/232-intravenous-vinorelbine-therapy-21-days.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00232c*</strong></p>
<p>Platinum refractory advanced ovarian carcinoma. </p>
</td>
</tr>
</tbody>
</table><table border="1" cellpadding="1" cellspacing="2" height="1885" summary="head and neck" width="820">
<caption> </caption>
<thead>
<tr align="left" valign="top">
<th id="th03438FE00000"><strong>Regimen Name</strong></th>
<th id="th03438FE00001"><strong>Indication</strong></th>
</tr>
</thead>
<tbody>
<tr align="left" valign="top">
<td>
<p><strong>CARBOplatin AUC (1.5) Chemoradiation Therapy-7 days</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/332-carboplatin-auc-1-5-chemoradiation-therapy-7-days.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00332a*</strong></p>
<p>Chemoradiation commencing 3 to 8 weeks after the completion of induction chemotherapy with TPF in patients with Stage III or IV locally advanced squamous cell carcinoma (SCC) of the head and neck. </p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CARBOplatin (AUC2) Weekly with Radiotherapy (RT)</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/419.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00419a</strong></p>
<p>Chemoradiation treatment of stage III and IV locally advanced nasopharyngeal carcinoma in patients where CISplatin is contraindicated or not tolerated.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CARBOplatin AUC 4 and 5-Fluorouracil 600mg/m2 with  <br/> Radiotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/591.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00591a</strong></p>
<p>Locally Advanced Squamous Cell Carcinoma of the Head and Neck</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p> </p>
<p><strong>CARBOplatin (AUC 5) and 5-Fluorouracil 1000mg/m<sup>2</sup>/day Therapy – 28 day cycle*</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/552.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00552a</strong></p>
<p>Adjuvant chemotherapy following chemoradiation treatment in patients with locally advanced stage III or IV nasopharyngeal carcinoma where CISplatin is contraindicated or not tolerated</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CARBOplatin 70mg/m2 and 5-Fluorouracil 600mg/m2 with Radiotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/589.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00589a</strong></p>
<p>Locally Advanced Squamous Cell Carcinoma of the Head and Neck.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Cetuximab Therapy- 7 days</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/207.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00207b</strong></p>
<p>Treatment of patients with squamous cell cancer of the head and neck: In combination with radiation therapy for locally advanced disease.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Cetuximab (weekly), Carboplatin AUC 5 and 5-FU 1000mg/m<sup>2</sup>/day Therapy - 21 day cycle</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/418.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00418a</strong></p>
<p>Locally advanced or metastatic squamous cell head and neck cancer where CISplatin is contraindicated or not tolerated</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Cetuximab (weekly), CISplatin 100mg/m<sup>2</sup> and 5-Fluorouracil 1000mg/m<sup>2</sup>/day Therapy-21 day cycle</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/417.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00417a</strong></p>
<p>Locally advanced or metastatic squamous cell carcinoma of the head and neck</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CISplatin 40mg/m<sup>2</sup> Weekly with Radiotherapy (RT)</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/385-cisplatin-40mg-m2-weekly-with-radiotherapy-rt-.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00385c</strong></p>
<p>Chemoradiation treatment for locally advanced nasopharnygeal carcinoma.</p>
<p><strong>00385d</strong></p>
<p>Chemoradiation treatment for locally advanced unresectable head and neck squamous carcinoma (SCC) in patients who cannot tolerate three weekly CISplatin regimens.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CISplatin 100mg/m<sup>2 </sup>with Radiotherapy (RT)</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/387-cisplatin-100-and-rt.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00387a</strong></p>
<p>Chemoradiation treatment for locally advanced (stage III to IV) squamous cell carcinoma (SCC) of the head and neck.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CISplatin and 5-Fluorouracil Therapy-28 day cycle</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/314-cisplatin-and-5-fluorouracil-therapy-28-day-cycle.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00314a</strong></p>
<p>Locally advanced or metastatic head and neck cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CYCLOPHOSPHamide, DOXOrubicin and CISplatin  Therapy – 21 Day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/615.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00615a</strong></p>
<p>Treatment of advanced salivary gland cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Neoadjuvant DOCEtaxel CISplatin 5-Fluorouracil and Chemoradiation and Surgery</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/315-neoadjuvant-docetaxel-cisplatin-5-fluorouracil-and-chemoradiation-and-surgery.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00315a</strong></p>
<p>Induction treatment of patients with Stage III or IV non-metastatic squamous cell carcinoma of the head and neck.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>DOCEtaxel,CISplatin ,5-Fluorouracil and Chemoradiation Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/323-docetaxel-cisplatin-5-fluorouracil-and-chemoradiation-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00323a</strong></p>
<p>Induction treatment of patients with locally advanced Stage III or IV non-metastatic squamous cell carcinoma of the head and neck.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>DOCEtaxel CISplatin 5-Fluorouracil and Radiotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/324-docetaxel-cisplatin-5-fluorouracil-and-radiotherapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00324a</strong></p>
<p>Induction treatment followed by radiotherapy of patients with Stage III or IV non-metastatic squamous cell carcinoma of the head and neck.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Gemcitabine (1250mg/m<sup>2</sup>) Monotherapy -21 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/514-gemcitabine-1250mg-m2-monotherapy-21-day.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00514a</strong></p>
<p>Loco-regionally recurrent/metastatic nasopharyngeal cancer not amenable for local curative therapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Gemcitabine (1250mg/m<sup>2</sup>) and CISplatin (80mg/m2) Therapy-21 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/517-gemcitabine-1250mg-m2-and-cisplatin-80mg-m2-therapy-21-day.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00517a</strong></p>
<p> Treatment of locally advanced nasopharyngeal cancer</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Lenvatinib_DTC Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/295.pdf"><strong>Regimen</strong></a></p>
</td>
<td>
<p><strong>00295a</strong></p>
<p>Treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Nivolumab 240mg Monotherapy - 14 Day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/483-nivolumab-240mg-monotherapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00483d</strong></p>
<p>As monotherapy for the treatment of squamous cell cancer of the head and neck in adults progressing on or after platinum-based therapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Nivolumab 480mg Monotherapy - 28 Day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/484-nivolumab-480mg-monotherapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00484e</strong></p>
<p>As monotherapy for the treatment of squamous cell cancer of the head and neck in adults progressing on or after platinum-based therapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Pembrolizumab 200mg Monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/pembrolizumab%20200mg%20monotherapy%20455.pdf">Regimen</a><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/455-pembrolizumab-200mg-monotherapy.pdf"></a></strong></p>
</td>
<td>
<p><strong>00455h</strong></p>
<p>As monotherapy for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS ≥ 1.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Pembrolizumab 400mg Monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/558-pembrolizumab-400-mg-monotherapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00558h</strong></p>
<p>As monotherapy for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS ≥ 1</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Pembrolizumab, CARBOplatin (AUC5) and 5-Fluorouracil Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/705-pembrolizumab-carboplatin-and-5-fu-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00705a</strong></p>
<p>Pembrolizumab is indicated, in combination with CARBOplatin and 5-fluorouracil, for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS ≥ 1.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Pembrolizumab, CISplatin and 5-Fluorouracil Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/706-pembrolizumab-cisplatin-and-5-fu-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00706a</strong></p>
<p>Pembrolizumab is indicated, in combination with CISplatin and 5-fluorouracil, for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS ≥ 1.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>SORAfenib Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/294-sorafenib-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00294c</strong></p>
<p>Treatment of patients with progressive, locally advanced or metastatic differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Vandetanib Monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/242vandetanibmonotherapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00242a</strong></p>
<p>Treatment of aggressive and symptomatic MTC in patients with unresectable locally advanced or metastatic disease</p>
</td>
</tr>
</tbody>
</table><table border="1" cellpadding="1" cellspacing="2" height="2977" summary="list of protocols">
<thead>
<tr align="left" valign="top">
<th id="th09D501300000"><strong>Regimen Name</strong></th>
<th id="th09D501300001"><strong>Indication</strong></th>
</tr>
</thead>
<tbody>
<tr align="left" valign="top">
<td>
<p><strong>Acalabrutinib Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/656-acalabrutinib-monotherapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00656a</strong></p>
<p>As monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy</p>
<p><strong>00656b</strong></p>
<p>As monotherapy for the treatment of previously untreated CLL in the presence of 17p deletion or TP53 mutation in adult patients unsuitable for chemoimmunotherapy</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Azacitidine 75mg/m<sup>2</sup> 5-2-2 Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/287-azacitidine-75mg-m2-5-2-2-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00287a</strong></p>
<p>Intermediate-1 and low risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS).</p>
<p><strong>00287b</strong></p>
<p>Treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with Intermediate-2 and high risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS).</p>
<p><strong>00287c</strong></p>
<p>Treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with Chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder.</p>
<p><strong>00287d</strong></p>
<p>Treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with Acute myeloid leukaemia (AML) with20-30% blasts and multi-lineage dysplasia, according to WHO classification.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong><strong>azaCITIDine</strong> 100mg/m<sup>2</sup> 5-day Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/288-azacitidine-100mg-m2-5-day-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00288a</strong></p>
<p>Intermediate-1 and low risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS).</p>
<p><strong>00288b</strong></p>
<p>Treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with Intermediate-2 and high risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS).</p>
<p><strong>00288c</strong></p>
<p>Treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with Chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder.</p>
<p><strong>00288d</strong></p>
<p>Treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with Acute myeloid leukaemia (AML) with 20-30% blasts and multi-lineage dysplasia, according to WHO classification.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Bendamustine Monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/527-bendamustine-monotherapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00527a</strong></p>
<p>Treatment of patients with relapsed or refractory Chronic Lymphocytic Leukaemia (CLL)</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Blinatumomab Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/538-blinatumomab-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00538a</strong></p>
<p>Treatment of adult patients with relapsed or refractory B cell precursor (BCP) Philadelphia chromosome negative acute lymphoblastic leukaemia (ALL) who have received no prior salvage treatment for relapsed/refractory (R/R) disease and are considered eligible for transplant (i.e. as a bridge-to-transplant).</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Blinatumomab Therapy (ALL with MRD ≥ 0.1%)</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/590-blinatumomab-mrd.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00590a</strong></p>
<p>As monotherapy for the treatment of adults with Philadelphia<br/>chromosome negative CD19 positive B-precursor acute lymphoblastic<br/>leukaemia (ALL) in first or second complete remission with minimal<br/>residual disease (MRD) greater than or equal to 0.1%</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Bosutinib Monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/224-bosutinib-monotherapy-regimen.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00224a</strong></p>
<p>Treatment of adult patients with chronic phase, accelerated phase, and blast phase Ph+CML previously treated with one or more TKI(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Chlorambucil 10mg/m<sup>2</sup> Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/411-chlorambucil-10mg-m2-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00411b</strong></p>
<p>Treatment of patients with Chronic Lymphocytic Leukaemia</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Cladribine 0.14mg/day Day 1 to 5 Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/402-cladribine-0-14mg-day-day-1-to-5-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00402a</strong></p>
<p>First line treatment for adult patients with Hairy Cell Leukaemia</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Cladribine 0.14mg/kg Weekly Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/469-cladribine-0-14mg-kg-weekly-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00469a</strong></p>
<p>First line treatment for adult patients with Hairy Cell Leukaemia</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Cladribine Weekly and riTUXimab Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/534-cladribine-weekly-and-rituximab-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00534a</strong></p>
<p>Treatment for adult patients with relapsed or partially responsive  Hairy Cell Leukaemia.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Cladribine 5 day and riTUXimab Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/531-cladribine-5-day-and-rituximab-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00531a</strong></p>
<p>Treatment for adult patients with relapsed or partially responsive  Hairy Cell Leukaemia.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>High Dose Cytarabine Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/365.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00365a</strong></p>
<p>Consolidation chemotherapy for the treatment of patients with Acute Myeloid Leukaemia (AML)</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Intermediate Dose Cytarabine Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/364.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00364a</strong></p>
<p>Consolidation chemotherapy for the treatment of patients Acute Myeloid Leukaemia (AML)</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>DA(60/100) 3+10: Course 1 Induction Therapy (AML-17)</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/359.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00359a</strong></p>
<p>Induction chemotherapy regimen for the treatment of patients with de novo or secondary Acute Myeloid Leukaemia (AML)</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>DA (50/100) (3+8) Course 2 Induction Therapy (AML-17)</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/360.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00360a</strong></p>
<p>Induction chemotherapy regimen for the treatment of patients with de novo or secondary Acute Myeloid Leukaemia (AML)</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Decitabine Monotherapy – AML (28 day cycle)</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/231.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00231a</strong></p>
<p>Treatment of adult patients aged 65 years and above with newly diagnosed de novo or secondary AML, according to the WHO classification, who are not candidates for standard induction chemotherapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Fedratinib Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/788-fedratinib-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00788a</strong></p>
<p>For the treatment of disease-related splenomegaly or symptoms in adult patients with:primary myelofibrosis (PMF),post polycythaemia vera myelofibrosis (PVMF) or post essential thrombocythaemia myelofibrosis (ET MF) who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>FLAG Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/363 flag therapy regimen .pdf">Regimen</a></p>
</td>
<td>
<p><strong>00363a</strong></p>
<p>Treatment of Acute Myeloid Leukaemia (AML) in patients unsuitable for treatment with idarubicin or as consolidation post FLAG-Ida.</p>
<p><strong>00363b</strong></p>
<p>Treatment of patients with high blast count (&gt;10%) Myelodysplastic Syndrome in patients unsuitable for treatment with idarubicin.</p>
<p><strong>00363c</strong></p>
<p>Salvage regimen for patients with relapsed/refractory acute leukaemia.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>FLAG: Ida 8mg/m<sup>2</sup> Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/362-flag-ida-8mg-m2-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00362a</strong></p>
<p>Induction of chemotherapy regimen for the treatment of patients with de novo, secondary Acute Myeloid Leukaemia (AML), or biphenotypic leukaemia.</p>
<p><strong>00362b</strong></p>
<p>Treatment of patients with blast count (&gt;10%) Myelodysplastic Syndrome</p>
<p><strong>00362c</strong></p>
<p>Salvage regimen for patients with relapsed/refractory acute leukaemia</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Fludarabine, Cyclophosamide and riTUXimab ( FC (IV) and R) Therapy</strong></p>
<p><strong></strong><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/241.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00241a</strong></p>
<p>Treatment of B-cell chronic lymphocytic leukaemia (CLL).</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Fludarabine, Cyclophosamide and riTUXimab ( FC (Oral) and R) Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/410-fcoral-and-r-fludarabine-cyclophosamide-and-rituximab-fc-oral-and-r-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00410a</strong></p>
<p>Treatment of B-cell chronic lymphocytic leukaemia (CLL).</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Gemtuzumab ozogamicin, DAUNOrubicin and Cytarabine Therapy (AML induction)</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/612-gemtuzumab-ozogamicin-therpay.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00612a</strong></p>
<p>Gemtuzumab ozogamicin is indicated for combination therapy with DAUNOrubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo CD33 positive Acute Myeloid Leukaemia (AML), except acute promyeloytic leukaemia</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Ibrutinib Therapy-CLL - Waldenström’s macroglobulinaemia</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/296.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00296a</strong></p>
<p>As a single agent for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.</p>
<p><strong>00296b</strong></p>
<p>As a single agent for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.</p>
<p><strong>00296c</strong></p>
<p>As a single agent for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Idelalisib and riTUXimab Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/idelalisib-and-rituximab-v2-389.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00389a</strong></p>
<p>In combination with riTUXimab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy</p>
<p><strong>00389b</strong></p>
<p>In combination with riTUXimab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Inotuzumab ozogamicin Monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/537-inotuzumab-ozogamicin-monotherapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00537a</strong></p>
<p>Monotherapy for the treatment of adults with relapsed or refractory CD22- positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Midostaurin Maintenance Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/661.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00661a</strong></p>
<p>Midostaurin is indicated as single agent maintenance therapy for adult patients with FLT3 mutation positive acute myeloid leukaemia (AML) in complete response after completion of induction and consolidation chemotherapy</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Midostaurin (DAUNOrubicin and Cytarabine) Induction Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/682.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00682a</strong></p>
<p>Midostaurin is indicated in combination with standard DAUNOrubicin and cytarabine induction chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Midostaurin and Intermediate Dose Cytarabine Consolidation Therapy </strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/683-midostaurin-intermediate-dose-cytarabine-consolidation-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00683a</strong></p>
<p>Midostaurin is indicated in combination with intermediate dose cytarabine consolidation</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Obinutuzumab and Chlorambucil Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/286 obinutuzumab-and-chlorambucil-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00286a</strong></p>
<p>Treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>PONATinib Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/302.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00302a</strong></p>
<p>Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.</p>
<p><strong>00302b</strong></p>
<p>Treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Ruxolitinib  Monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/229-ruxolitinib-monotherapy-regimen.pdf">Regimen</a></strong></p>
</td>
<td>
<p>The treatment of disease-related splenomegaly or symptoms in adult patients with:</p>
<p><strong>00229a</strong></p>
<p>Primary myelofibrosis (chronic idiopathic myelofibrosis)</p>
<p><strong>00229b</strong></p>
<p>Post polycythaemia vera myelofibrosis</p>
<p><strong>00229c</strong></p>
<p>Post essential thrombocythaemia myelofibrosis</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Tretinoin (ATRA) with Arsenic Trioxide (ATO) Induction Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/356-tretinoin-atra-with-arsenic-trioxide-ato-induction-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00356a</strong></p>
<p>Treatment of patients with newly diagnosed low to intermediate risk Acute Promyelocytic Leukaemia (APL)</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Tretinoin (ATRA) with Arsenic Trioxide (ATO) Consolidation Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/357-tretinoin-atra-with-arsenic-trioxide-ato-consolidation-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00357a</strong></p>
<p>Treatment of patients with low to intermediate risk Acute Promyelocytic Leukaemia (APL) with haematological complete remission (CR) after induction treatment with tretinoin (ATRA) and arsenic trioxide (Ref NCCP Protocol 00356).</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Tretinoin (ATRA)IDArubicin (PETHEMA AIDA) Induction Therapy:High Risk</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/366-tretinoin-atra-idarubicin-pethema-aida-induction-therapy-high-risk.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00366a</strong></p>
<p>Treatment of patients with newly diagnosed high risk Acute Promyelocytic Leukaemia (APL)</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Venetoclax Monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/400.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00400a</strong></p>
<p>Treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.</p>
<p><strong>00400b</strong></p>
<p>Treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Venetoclax and obinutuzumab Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/715.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00715a</strong></p>
<p>In combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Venetoclax and riTUXImab Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/575-venetoclax-and-rituximab-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00575a</strong></p>
<p>Venetoclax in combination with riTUXimab is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Vyxeos liposomal® DAUNOrubicin and Cytarabine Induction Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/613-vxyeos-%C2%AE-liposomal-daunorubicin-and-cytarabine-induction-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00613a</strong></p>
<p>For the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Vyxeos liposomal® DAUNOrubicin and Cytarabine Consolidation Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/618-vxyeos%C2%AE-liposomal-daunorubicin-and-cytarabine-consolidation-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00618a</strong></p>
<p>For the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)</p>
</td>
</tr>
</tbody>
</table><table border="1" cellpadding="1" cellspacing="2" height="4178" summary="list of protocols">
<thead>
<tr align="left" valign="top">
<th id="th0829EB880000"><strong>Regimen Name</strong></th>
<th id="th0829EB880001"><strong>Indication</strong></th>
</tr>
</thead>
<tbody>
<tr align="left" valign="top">
<td>
<p><strong>Afatinib Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/221.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00221a</strong></p>
<p>Treatment of EGFR TKI- naïve adult patients with locally advanced or metastatic NSCLC with activating EGFR mutation(s).</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Alectinib Monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/401 .pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00401a</strong></p>
<p>Treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.</p>
<p><strong>00401b</strong></p>
<p>As monotherapy is indicated for the first-line treatment of adult<br/>patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Atezolizumab 1200mg Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/544-atezolizumab-1200mg-monotherapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00544a</strong></p>
<p>Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy.</p>
<p><strong>00544d</strong></p>
<p>first-line treatment of adult patients with<br/>metastatic non-small cell lung cancer (NSCLC) whose tumours have a PDL1<br/>expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating<br/>immune cells (IC) and who do not have EGFR mutant or ALK-positive<br/>NSCLC</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Atezolizumab 1680mg Monotherapy – 28 Day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/593-atezolizumab-1680mg-monotherapy-28-day.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00593a</strong></p>
<p>Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy.</p>
<p><strong>00593d</strong></p>
<p>First-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PDL1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Atezolizumab 840mg Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/592-atezolizumab-840mg-monotherapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00592d</strong></p>
<p>As monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PDL1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.<strong></strong></p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Atezolizumab 1200mg, CARBOplatin AUC 5 and Etoposide 100mg/m2 Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/689.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00689a</strong></p>
<p>First-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Bevacizumab 7.5 mg/kg –21 days</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/bevacizumab7-5v7214.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00214b</strong></p>
<p>In addition to platinum-based chemotherapy is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) other than predominantly squamous cell histology.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Bevacizumab 15mg/kg Therapy- 21 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/215.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00215f</strong></p>
<p>In addition to platinum-based chemotherapy is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) other than predominantly squamous cell histology.</p>
<p><strong>00215g</strong></p>
<p>In combination with erlotinib is indicated for the first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous cell lung cancer with Epidermal Growth Factor (EGFR) activating mutations.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Brigatinib Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/562-brigatinib-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00562a</strong></p>
<p>For the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.</p>
<p><strong>00562b</strong></p>
<p>Monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CARBOplatin (AUC5) and Etoposide 100mg/m<sup>2</sup> Therapy-21 days </strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/271.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00271a</strong></p>
<p>Small cell lung cancer (SCLC) extensive disease.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CARBOplatin and Oral Etoposide Therapy-21 days</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/319-carboplatin-and-oral-etoposide-therapy-21-days.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00319a</strong></p>
<p>Small cell lung cancer (SCLC) extensive disease.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CARBOplatin (AUC6) and PACLitaxel 200mg/m<sup>2</sup> Therapy* </strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/304-carboplatin-auc6-and-paclitaxel-200mg-m2-therapy-.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00304a</strong></p>
<p>Adjuvant Treatment of Stage I,II and IIIA Non Small Cell Lung Cancer( NSCLC)<sup>*</sup></p>
<p><strong>00304b</strong></p>
<p>Treatment of locally advanced, recurrent or metastatic NSCLC<sup>*</sup></p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Weekly CARBOplatin (AUC2) and PACLitaxel 50mg/m<sup>2</sup> Therapy with Radiotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/309-weekly-carboplatin-auc2-and-paclitaxel-50mg-m2-therapy-with-radiotherapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00309a</strong></p>
<p>Stage III Non small cell lung cancer (NSCLC)*</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CARBOplatin and vinORELbine Therapy-21 Day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/614.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00614a</strong></p>
<p>Treatment of locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC) in patients not suitable for treatment with CISplatin.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Ceritinib Monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/340-ceritinib-monotherapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00340a</strong></p>
<p>Treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CISplatin and Etoposide</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/280%20ver%204.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00280a</strong></p>
<p>Small cell lung cancer (SCLC) extensive disease</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CISplatin and Etoposide and Thoracic Radiotherapy (TRT)</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/279-nccp-cisplatin-and-etoposide-ver2final.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00279a</strong></p>
<p>Small cell lung cancer (SCLC) limited disease</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CISplatin (50mg/m<sup>2</sup>) and Etoposide (50mg/m<sup>2</sup>) and Thoracic Radiotherapy (TRT) -28 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/456-cisplatin-50mg-m2-and-etoposide-50mg-m2-and-thoracic-radiotherapy-trt-28-day.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00456a</strong></p>
<p>Stage III Non Small cell lung cancer (NSCLC).</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Crizotinib Monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/243-crizotinib-monotherapy-regimen.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00243a</strong></p>
<p>Treatment of adults with previously treated ALK-positive advanced NSCLC</p>
<p><strong>00243b</strong></p>
<p>The treatment of adults with ROS1-positive advanced non-small cell<br/>lung cancer (NSCLC)</p>
<p><strong>00243c</strong></p>
<p>First-line treatment of adults with anaplastic lymphoma kinase<br/>(ALK)-positive advanced non-small cell lung cancer (NSCLC)</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Dacomitinib Monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/565-dacomitinib-monotherapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00565a</strong></p>
<p>Monotherapy, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>DOCEtaxel Monotherapy 75mg/m<sup>2</sup> – 21 day cycle</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/203.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00203a</strong></p>
<p>Treatment of locally advanced or metastatic NSLC after failure of prior chemotherapy</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Durvalumab 10mg/kg Monotherapy-14 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/576.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00576a</strong></p>
<p>As monotherapy is indicated for the treatment of locally advanced, unresectable NSCLC in adults whose tumours express PD-L1 ≥1% on tumour cells and whose disease has not progressed following platinum-based chemo-radiation therapy (CRT).</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Durvalumab 1500mg Monotherapy-28 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/655-durvalumab-1500mg-monotherapy-28-day.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00655a</strong></p>
<p>As monotherapy is indicated for the treatment of locally advanced, unresectable NSCLC in adults whose tumours express PD-L1 ≥1% on tumour cells and whose disease has not progressed following platinum-based chemo-radiation therapy (CRT)</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Entrectinib Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/702-entrectinib-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00702a</strong></p>
<p>As monotherapy for the treatment of adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Erlotinib Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/219.pdf"><strong>Regimen</strong></a></p>
</td>
<td>
<p><strong>00219a</strong></p>
<p>First-line treatment of patients with locally advanced or metastatic non- small cell lung cancer (NSCLC) with EGFR activating mutations.</p>
<p><strong>00219b</strong></p>
<p>Switch maintenance treatment in patients with locally advanced or metastatic NSCLC with EGFR activating mutations and stable disease after first-line chemotherapy.</p>
<p><strong>00219c</strong></p>
<p>Treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Oral Etoposide Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/388.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00388a</strong></p>
<p>Small cell lung cancer (SCLC) extensive disease in patients unsuitable for intravenous or combination chemotherapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Gefitinib Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/220-gefitinib-monotherapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00220a</strong></p>
<p>Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong><strong>Gemcitabine 1000mg/m<sup>2</sup> Monotherapy- 28 day</strong></strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/284-gemcitabine-1000mg-m2-monotherapy-28-day.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00284b</strong></p>
<p>Treatment of elderly patients or patients with ECOG =2 with locally advanced or metastatic non-small cell lung cancer (NSCLC)</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Gemcitabine (1000mg/m<sup>2</sup>) and CARBOplatin (AUC5) Therapy-21 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/310.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00310b</strong></p>
<p>Treatment of patients with locally advanced, recurrent or metastatic non small cell lung cancer (NSCLC)<sup>*</sup></p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Gemcitabine (1250mg/m<sup>2</sup>) and CISplatin 75mg/m<sup>2 </sup>Therapy-21day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/281-gemcitabine-1250mg-m2-and-cisplatin-75mg-m2-therapy-21days.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00281a</strong></p>
<p>Treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Lorlatinib therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/570%20lorlatinib%20therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00570a</strong></p>
<p>As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), following disease progression on</p>
<p>(i) alectinib or ceritinib as the first ALK-targeted treatment</p>
<p>or</p>
<p>(ii) crizotinib and at least one other ALK-targeted treatment</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Lorlatinib therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/570%20lorlatinib%20therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00570b</strong></p>
<p>As monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously not treated with an ALK inhibitor.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong><br/>Nintedanib Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/372.pdf"><strong></strong></a><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/nintedanib-therapy-v5-372.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00372a</strong></p>
<p>In combination with docetaxel for the treatment of adult patients with locally advanced, metastatic of stage IIIB or IV, or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Nivolumab Monotherapy 240mg-14 days</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/483-nivolumab-240mg-monotherapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00483e<br/></strong></p>
<p>As monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Nivolumab Monotherapy 480mg-28 days</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/484-nivolumab-480mg-monotherapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00484f</strong></p>
<p>As monotherapy for the treatment of locally advanced or metastatic non small cell lung cancer (NSCLC) after prior chemotherapy in adults.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Nivolumab, ipilimumab, CARBOplatin and PACLitaxel Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/712.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00712a</strong></p>
<p>First-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitising EGFR mutation or ALK translocation.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Nivolumab, ipilimumab, PEMEtrexed and CARBOplatin Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/713.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00713a</strong></p>
<p>First-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitising EGFR mutation or ALK translocation.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Nivolumab, ipilimumab, PEMEtrexed and CISplatin Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/714.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00714a</strong></p>
<p>First-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitising EGFR mutation or ALK translocation.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Osimertinib Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/353-osimertinib-monotherapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00353a</strong></p>
<p>Treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC)</p>
<p><strong>00353b</strong></p>
<p>First-line treatment of adult patients with locally advanced or metastatic<br/>non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/226-paclitaxel-monotherapy-80mg-m2-7day-cycle.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00226d</strong></p>
<p>Relapsed or refractory small cell lung cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/621.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00621d</strong></p>
<p>Relapsed or refractory small cell lung cancer.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Pembrolizumab 200mg Monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/pembrolizumab%20200mg%20monotherapy%20455.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00455a</strong></p>
<p>First-line treatment of metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 with a ≥50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong><strong><strong><strong>Pembrolizumab 400 mg monotherapy</strong></strong></strong></strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/pembrolizumab-400mg-monotherapy-558.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00558a</strong></p>
<p>First-line treatment of metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 with a ≥50% tumour proportion score (TPS) with no EGFR mutations or ALK translocations.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Pembrolizumab, PACLitaxel and CARBOplatin (AUC 6) Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/579.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00579a</strong></p>
<p>Pembrolizumab In Combination with CARBOplatin and PACLitaxel for the first-line treatment of Patients with metastatic Squamous Non-Small Cell Lung Cancer (NSCLC).</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/568.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00568a</strong></p>
<p>Pembrolizumab is indicated in combination with PEMEtrexed and CARBOplatin for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumors have no EGFR or ALK positive mutations.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Pembrolizumab, PEMEtrexed and CISplatin Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/569.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00569a</strong></p>
<p>Pembrolizumab is indicated in combination with PEMEtrexed and CISplatin for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumors have no EGFR or ALK positive mutations.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>PEMEtrexed Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/222-pemetrexed-monotherapy-regimen.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00222a</strong></p>
<p>Maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients who disease has not progressed immediately following platinum-based chemotherapy.</p>
<p><strong>00222b</strong></p>
<p>Second line treatment of patients with locally advanced or metastatic NSLC other than predominantly squamous cell histology.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>PEMEtrexed and CARBOplatin Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/318-pemetrexed-and-carboplatin-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00318a</strong></p>
<p>Treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.</p>
<p><strong>00318b</strong></p>
<p>First line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) other than predominantly squamous cell histology.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>PEMEtrexed and CISplatin Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/317-pemetrexed-and-cisplatin-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00317a</strong></p>
<p>Treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.</p>
<p><strong>00317b</strong></p>
<p>First line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong><strong>Topotecan Monotherapy-5 day</strong></strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/311-topotecan-monotherapy-5-day.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00311b</strong></p>
<p>Treatment of patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong><strong>Topotecan Oral Monotherapy</strong></strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/587-topotecan-oral-monotherapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00587a</strong></p>
<p>Treatment of adult patients with relapsed small cell lung cancer<br/>(SCLC) for whom re-treatment with the first –line regimen is not<br/>considered appropriate</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Oral Vinorelbine Monotherapy 7 days</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/259.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00259b</strong></p>
<p>Non small cell lung cancer (NSLC)</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Intravenous Vinorelbine Therapy-21 days</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/232-intravenous-vinorelbine-therapy-21-days.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00232b</strong></p>
<p>Non small cell lung cancer (NSLC)</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong><strong><strong><strong>Vinorelbine and CISplatin Therapy-28 days</strong></strong></strong></strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/343-vinorelbine-and-cisplatin-therapy-28-days.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00343a</strong></p>
<p>Adjuvant treatment of patients with completely resected stage IB, ll or lllA non small cell lung cancer (NSLC).</p>
<p><strong>00343b</strong></p>
<p>Treatment of locally advanced recurrent or metastatic NSCLC.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Vinorelbine 30 (Day 1, 8, 15) and CISplatin 80 (Day 1) Therapy-21 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/339-vinorelbine-30-day-1-8-15-and-cisplatin-80-day-1-therapy-21-day.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00339a</strong></p>
<p>Adjuvant treatment of patients with completely resected stage IB, ll or lllA non small cell lung cancer (NSLC).</p>
<p><strong>00339b</strong></p>
<p>Treatment of locally advanced recurrent or metastatic NSCLC.</p>
</td>
</tr>
</tbody>
</table><table border="1" cellpadding="1" cellspacing="2" height="4076" summary="list of renal protocols" width="823">
<thead>
<tr align="left" valign="top">
<th id="th0CE300280000"><strong>Regimen Name</strong></th>
<th id="th0CE300280001"><strong>Indication</strong></th>
</tr>
</thead>
<tbody>
<tr align="left" valign="top">
<td>
<p><strong>ABVD Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/290-abvd-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00290a</strong></p>
<p>Hodgkin’s Lymphoma.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Bendamustine Monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/527-bendamustine-monotherapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00527a</strong></p>
<p>Treatment of patients with relapsed or refractory Chronic Lymphocytic Leukaemia (CLL)</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Brentuximab vedotin Monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/234-brentuximab-vedotin-monotherapy-regimen.pdf">Regimen</a></strong></p>
</td>
<td>
<p>Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL):</p>
<p><strong>00234a</strong></p>
<p>Following autologous stem cell transplant (ASCT)</p>
<p>or</p>
<p><strong>00234b</strong></p>
<p>Following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option</p>
<p><strong>00234c</strong></p>
<p>Treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL)</p>
<p><strong>00234d</strong></p>
<p>Treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.</p>
<p><strong>00234e</strong></p>
<p>Treatment of adult patients with CD30+ Hodgkins Lymphoma (HL) at increased risk of relapse or progression following an autologous haematopoietic stem cell transplant (ASCT).</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Brentuximab vedotin and Bendamustine Therapy*</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/529-brentuximab-vedotin-and-bendamustine-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00529a</strong></p>
<p>Treatment of adult patients with relapsed or refractory CD30+ Hodgkin<br/>lymphoma (HL)</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Brentuximab vedotin and ESHAP therapy(BRESHAP)*</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/530.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00530a</strong></p>
<p>Treatment of adult patients with relapsed/refractory CD30+ Hodgkin’s lymphoma.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Brentuximab vedotin and cyclophosphamide, DOXOrubicin and prednisolone (CHP) Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/801-brentuximab-vedotin-and-cyclophosphamide-doxorubicin-and-prednisolone-chp-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00801a</strong></p>
<p>Brentuximab vedotin in combination with cyclophosphamide, DOXOrubicin and prednisoLONE (CHP) for use in adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL)</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Brentuximab vedotin and ICE Therapy*</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/528.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00528</strong></p>
<p>Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL).</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Chlorambucil 10mg/m<sup>2</sup> Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/411-chlorambucil-10mg-m2-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00411a</strong></p>
<p>Treatment of patients with low grade lymphoma.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>CHOEP Therapy-21 days</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/396.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00396a</strong></p>
<p>Treatment of T-cell Non-Hodgkins Lymphoma.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Cladribine 5 day and riTUXimab Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/531-cladribine-5-day-and-rituximab-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00531a</strong></p>
<p>Treatment for adult patients with relapsed or partially responsive  Hairy Cell Leukaemia</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Cladribine Weekly and riTUXimab Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/534-cladribine-weekly-and-rituximab-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00534a</strong></p>
<p>Treatment for adult patients with relapsed or partially responsive  Hairy Cell Leukaemia</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Cladribine 0.14mg/day Day 1 to 5 Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/402-cladribine-0-14mg-day-day-1-to-5-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00402a</strong></p>
<p>First line treatment for adult patients with Hairy Cell Leukaemia</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Cladribine 0.14mg/kg Weekly Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/469-cladribine-0-14mg-kg-weekly-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00469a</strong></p>
<p>First line treatment for adult patients with Hairy Cell Leukaemia<strong></strong></p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Cyclophosphamide 2000mg/m<sup>2</sup> For Stem Cell Mobilisation</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/438-cyclophosphamide-2000mg-m2-for-stem-cell-mobilisation.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00438a</strong></p>
<p>Mobilisation of peripheral blood stem cells for future stem cell rescue following high dose chemotherapy</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Cyclophosphamide 1500mg/m2 For Stem Cell Mobilisation</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/795-cyclophosphamide-for-stem-cell-mobilisation.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00795a</strong></p>
<p>Mobilisation of peripheral blood stem cells for future stem cell rescue following high dose chemotherapy</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Dexamethasone, riTUXimab and Cyclophosphamide (DRC) Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/532-dexamethasone-rituximab-and-cyclophosphamide-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00532a</strong></p>
<p>Treatment of symptomatic treatment naive or relapsed/refractory Waldenstrom’s macroglobulinaemia</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Dose Adjusted R-EPOCH Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/355-dose-adjusted-r-epoch-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00355a</strong></p>
<p>Treatment of patients with CD20 positive diffuse large B-cell Non Hodgkins lymphoma (NHL).</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Escalated Dose BEACOPP 21 day Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/354-escalated-dose-beacopp-21-day-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00354a</strong></p>
<p> Treatment of patients with high risk, advanced stage Hodgkin Lymphoma (IPS ≥ 3)</p>
<p><strong>00354b</strong></p>
<p>Escalation of treatment of patients with Hodgkin Lymphoma after failure to reach complete metabolic response post 2 cycles of ABVD</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Ibrutinib Therapy-CLL Waldenström’s macroglobulinaemia</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/296.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00296a</strong></p>
<p>As a single agent for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.</p>
<p><strong>00296b</strong></p>
<p>As a single agent for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.</p>
<p><strong>00296c</strong></p>
<p>As a single agent for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Ibrutinib Therapy (Mantle Cell Lymphoma)</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/297.pdf"><strong>Regimen</strong></a></p>
</td>
<td>
<p><strong>00297a</strong></p>
<p>As a single agent for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Idelalisib Monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/291.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00291a</strong></p>
<p>Monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>High dose Methotrexate, high dose Cytarabine, riTUXimab and Thiotepa (MATRix)Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/508-high-dose-methotrexate-high-dose-cytarabine-rituximab-and-thiotepa-matrix-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00508a</strong></p>
<p>Treatment of primary CNS lymphoma</p>
<p><strong>00508b</strong></p>
<p>Treatment of CNS relapse of a high grade systemic lymphoma</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Nivolumab 240mg Monotherapy - 14 Day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/483-nivolumab-240mg-monotherapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00483c</strong></p>
<p>As monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Nivolumab 480mg-28days</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/484-nivolumab-monotherapy-480mg-28-days.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00484d</strong></p>
<p>As monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Nordic Therapy Protocol</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/393-nordic-therapy-regimen.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00393a</strong></p>
<p>Mantle Cell Lymphoma.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Obinutuzumab Maintenance Therapy - 56 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/425%20obinutuzumab-maintenance-therapy-following-o-bendamustine-therapy1.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00425a</strong></p>
<p>Obinutuzumab maintenance therapy is indicated in patients with follicular lymphoma (FL) who have responded to induction treatment with obinutuzumab and chemotherapy (CHOP, CVP or bendamustine) or have stable disease.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Obinutuzumab and Bendamustine Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/424-obinutuzumab-and-bendamustine-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00424a</strong></p>
<p>Obinutuzumab in combination with bendamustine is indicated for the treatment of patients with follicular lymphoma (FL) who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.</p>
<p><strong>00424b</strong></p>
<p>Obinutuzumab in combination with bendamustine is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Obinutuzumab Cyclophosphamide VinCRIStine and Prednisolone (O- CVP) Therapy– 21 days</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/550-obinutuzumab-cyclophosphamide-vincristine-and-prednisolone-o-cvp-therapy%E2%80%93-21-days.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00550a</strong></p>
<p>Obinutuzumab in combination with CVP chemotherapy is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Obinutuzumab and CHOP Therapy – 21 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/549-obinutuzumab-and-chop-therapy-%E2%80%93-21-day.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00549a</strong></p>
<p>Obinutuzumab in combination with CHOP chemotherapy is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Pembrolizumab 200mg Monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/pembrolizumab%20200mg%20monotherapy%20455.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00455i</strong></p>
<p>As monotherapy for the treatment of adult patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Pembrolizumab 400mg monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/pembrolizumab-400mg-monotherapy-558.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00558i</strong></p>
<p>As monotherapy for the treatment of adult patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Pixantrone Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/255-nccp-pixantrone-ver2final-.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00255a</strong></p>
<p>Monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non-Hodgkin B-cell Lymphomas (NHL).</p>
<p>The benefit of pixantrone treatment has not been established in patients when used as fifth line or greater chemotherapy in patients who are refractory to last therapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Plerixafor and G-CSF Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/536-plerixafor-and-g-csf-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00536a</strong></p>
<p>Is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma and multiple myeloma whose cells mobilise poorly </p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Polatuzumab Vedotin, Bendamustine and riTUXimab Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/685-polatuzumab-vedotin-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00685a</strong></p>
<p>Polatuzumab Vedotin in combination with bendamustine and riTUXimab for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>riTUXimab, Methotrexate, Procarbazine and vinCRIStine (R-MPV) – 14 Days Induction Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/664-rituximab-methotrexate-procarbazine-and-vincristine-r-mpv-14-days-induction-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00664a</strong></p>
<p>Treatment of newly diagnosed primary CNS lymphoma (PCNSL)</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>High Dose Cytarabine Consolidation Therapy (post RMPV) - 28 day Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/666-high-dose-cytarabine-consolidation-therapy-post-rmpv-28-day-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00666a</strong></p>
<p>Consolidation chemotherapy for the treatment of patients with newly diagnosed primary CNS lymphoma (PCNSL)</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>riTUXimab 375 mg/m<sup>2</sup> Maintenance Therapy-84 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/rituximab-375-mg-m2-maintenance-therapy-84-day.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00540a</strong></p>
<p>Maintenance therapy for the treatment of relapsed/refractory follicular CD20<br/>positive, B-cell Non Hodgkin Lymphoma (NHL) in patients who have<br/>responded to induction therapy</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>riTUXimab 375 mg/m<sup>2</sup> Therapy-7 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/541-rituximab-375-mg-m2-therapy-7-day.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00541a</strong></p>
<p>First line treatment of follicular lymphoma</p>
<p><strong>00541b</strong></p>
<p>As monotherapy for induction treatment for adult patients with stage<br/>III-IV follicular lymphoma who are chemoresistant or are in their second<br/>or subsequent relapse after chemotherapy</p>
<p><strong>00541c</strong></p>
<p>As monotherapy for retreatment of patients who have responded to<br/>previous treatment with riTUXimab monotherapy for<br/>relapsed/refractory follicular lymphoma,</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>riTUXimab 375 mg/m<sup>2</sup> Combination Therapy-21 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/542-rituximab-375-mg-m2-combination-therapy-21-day.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00542a</strong></p>
<p>In combination with chemotherapy for induction treatment of<br/>previously untreated or relapsed/ refractory CD 20 positive patients<br/>with follicular lymphoma</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>riTUXimab 375 mg/m<sup>2</sup> Maintenance Therapy- 56 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/543-rituximab-375-mg-m2-maintenance-therapy-56-day.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00543a</strong></p>
<p>Maintenance therapy for the treatment of previously untreated follicular<br/>CD20 positive, B-cell Non Hodgkin Lymphoma patients responding to<br/>induction therapy</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>RiTUXimab (S/C 1400mg) Maintenance Therapy-84 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/599.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00599a</strong></p>
<p>Maintenance therapy for the treatment of relapsed/refractory follicular CD20 positive, B-cell Non Hodgkin Lymphoma (NHL) in patients who have responded to induction therapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>RiTUXimab (S/C 1400mg) Maintenance Therapy- 56 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/600.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00600a</strong></p>
<p>Maintenance therapy for the treatment of previously untreated follicular CD20 positive, B-cell Non Hodgkin Lymphoma patients responding to induction therapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>riTUXimab and Bendamustine Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/345.pdf"><strong>Regimen</strong></a></p>
</td>
<td>
<p><strong>00345a</strong></p>
<p>Treatment of patients with previously untreated indolent CD20-positive, stage III-IV non-hodgkin lymphoma (NHL).</p>
<p><strong>00345b</strong></p>
<p>Treatment of patients with previously untreated CD20-positive, stage III-IV mantle cell lymphoma (MCL), ineligible for autologous stem cell transplant.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>R-CEOP Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/510-r-ceop-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00510a</strong></p>
<p>Treatment of Non Hodgkin CD20 positive Lymphoma for patients not suitable for anthracycline therapy</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>(*riTUXimab) Cyclophosphamide, DOXOrubicin, vinCRIStine and Prednisolone (*R)-CHOP Therapy– 14 days</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/409.pdf"><strong>Regimen</strong></a></p>
</td>
<td>
<p><strong>00409a</strong></p>
<p>Treatment of Non Hodgkins Lymphoma (NHL)*</p>
<p>*Rituximab to be included in CD20 positive patients</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>(*Rituximab) Cyclophosphamide, DOXOrubicin, VinCRIStine and Prednisolone (*R)-CHOP) Therapy– 21 days</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/307.pdf"><strong>Regimen</strong></a></p>
</td>
<td>
<p><strong>00307a</strong></p>
<p>Treatment of Non Hodgkins Lymphoma (NHL).*</p>
<p>*Rituximab to be included in CD20 positive patients.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>(R**)- miniCHOP Therapy – 21 days</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/436-r-minichop-therapy-%E2%80%93-21-days.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00436a</strong></p>
<p>Treatment of Non Hodgkin Lymphoma in patients aged greater than 80 or with significant co-morbidities.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>R-CODOX-M Therapy Patients less than or equal to 65 years</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/398-r-codox-m-therapy-patients-less-than-or-equal-to-65-years-.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00398a</strong></p>
<p>Treatment of Burkitt Lymphoma in patients less than or equal to 65 years.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>R-CODOX-M Therapy Patients greater than 65 years</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/403-r-codox-m-therapy-patients-greater-than-65-years-.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00403a</strong></p>
<p>Treatment of Burkitt Lymphoma in patients aged greater than 65 years.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>(R**)-DHAP Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/395-r-dhap-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00395a</strong></p>
<p>Treatment of relapsed Non Hodgkin Lymphoma**</p>
<p>**Rituximab to be included in CD20 positive patients</p>
<p><strong>00395b</strong></p>
<p>Treatment of relapsed Hodgkins Lymphoma</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>(R**)-ESHAP Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/394-r-eshap-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00394a</strong></p>
<p>Treatment of relapsed Non Hodgkin Lymphoma</p>
<p><strong>00394b</strong></p>
<p>Treatment of relapsed Hodgkins Lymphoma</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>riTUXimab** Gemcitabine and CISplatin ((R**)-GDP) Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/441-rituximab-gemcitabine-dexamethasone-and-cisplatin-r-gdp-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00441a</strong></p>
<p>Treatment of relapsed Non Hodgkin Lymphoma</p>
<p><strong>00441b</strong></p>
<p>Treatment of relapsed Hodgkin’s Lymphoma</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>R-Gemcitabine (1000mg/m<sup>2</sup>) Oxaliplatin Therapy[i] - 14 day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/506.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00506a </strong></p>
<p>Relapsed or refractory CD20 positive diffuse large B cell lymphoma in patients ineligible for stem cell transplant.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p> </p>
</td>
<td>
<p> </p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>riTUXimab-Hyper CVAD Therapy (MCL)-Part A</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/466-rituximab-hyper-cvad-therapy-mcl-part-a.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00466a</strong></p>
<p>Treatment of adult patients with mantle cell lymphoma</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>riTUXimab-Methotrexate and Cytarabine Therapy (MCL)-Hyper CVAD Part B</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/467-rituximab-methotrexate-and-cytarabine-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00467a</strong></p>
<p>Treatment of adult patients with mantle cell lymphoma</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong> (R**)-ICE ((RiTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/397.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00397a</strong></p>
<p>Treatment of relapsed/refractory Non Hodgkin’s Lymphoma**</p>
<p>**Rituximab to be included in CD20 positive patients.</p>
<p><strong>00397b</strong></p>
<p>Treatment of relapsed/refractory Hodgkin’s Lymphoma.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>R-IVAC Therapy Patients less than or equal to 65 years</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/399-r-ivac-therapy-patients-less-than-or-equal-to-65-years-.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00399a</strong></p>
<p>Treatment of patients with extensive stage  Burkitt Lymphoma aged less than or equal to 65 years.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>R-IVAC Therapy</strong> <strong>Patients greater than 65 years</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/404-r-ivac-therapy-patients-greater-than-65-years-.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00404a</strong></p>
<p>Treatment of patients with extensive Burkitt Lymphoma aged greater than  65 years.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>(*riTUXimab) Cyclophosphamide and PrednisoLONE (R*)-CVP ) Therapy-21 days </strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/293.pdf"><strong></strong></a><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/r cvp v3 293.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00293a</strong></p>
<p>First line treatment for patients with stage 3/4 follicular lymphoma</p>
<p><strong>00293b</strong></p>
<p>Treatment of patients with relapsed/refractory low grade B cell Non Hodgkin’s lymphoma (NHL)*</p>
<p>*Rituximab to be included in CD20 positive patients.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>(*riTUXimab)-Gemcitabine Cyclophosphamide vinCRIStine and PrednisoLONE (*R)-GCVP) Therapy–21 days</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/737-rituximab-gemcitabine-cyclophosphamide-vincristine-and-prednisolone-r-gcvp-therapy21-days.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00737a</strong></p>
<p>Treatment of high-grade non-Hodgkin Lymphoma in patients who are unsuitable for R-CHOP due to impaired cardiac function or other comorbidities*</p>
<p>*riTUXimab to be included in CD20 positive patients</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Siltuximab Monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/277-siltuximab.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00277a</strong></p>
<p>Treatment of adult patients with Multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpes virus 8 (HHV-8) negative.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>SMILE Therapy (NK or T cell Lymphoma)</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/407-smile-therapy-nk-or-t-cell-lymphoma-.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00407a</strong></p>
<p>Newly diagnosed stage II- IV or relapsed/refractory extranodal natural killer/T-cell lymphoma</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Zanubrutinib Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/708-zanubrutinib-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00708</strong></p>
<p>As monotherapy for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM), who have received at least one prior therapy or<br/>as first line treatment for patients unsuitable for chemo-immunotherapy</p>
</td>
</tr>
</tbody>
</table><table border="1" cellpadding="1" cellspacing="2">
<tbody>
<tr>
<td><strong>Regimen Name</strong></td>
<td><strong>Indication</strong></td>
</tr>
<tr>
<td>
<p><strong>Bortezomib and Dexamethasone Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/270.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00270a</strong></p>
<p>Treatment of adult patients with progressive multiple myeloma who have received at least one prior therapy.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Bortezomib Maintenance Therapy- 14 day</strong></p>
<p> <a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/435-bortezomib-maintenance-therapy-14-day-.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00435a</strong></p>
<p>Maintenance treatment for patients with high risk  multiple myeloma</p>
</td>
</tr>
<tr>
<td class="left">
<p><strong>Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy-21 day*</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/416.pdf">Regimen</a></p>
</td>
<td class="left">
<p><strong>00416a</strong></p>
<p>Treatment of newly diagnosed myeloma in adult patients with high risk features.</p>
<p><strong>00416b</strong></p>
<p>Treatment of relapsed or refractory myeloma that has received prior therapy in adult patients with high risk features.</p>
</td>
</tr>
<tr>
<td class="left">
<p><strong>Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy- 28 day*</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/643.pdf">Regimen</a></p>
</td>
<td class="left">
<p><strong>00643a</strong></p>
<p>Treatment of Myeloma.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Bortezomib, Melphalan and Prednisolone Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/275-bortezomib-melphalan-and-prednisolone-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00275a</strong></p>
<p>Treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Bortezomib, Lenalidomide and Dexamethasone (RVD-Lite) Induction Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/780-bortezomib-lenalidomide-and-dexamethasone.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00780a</strong></p>
<p> Treatment of newly diagnosed multiple myeloma patients who are transplant ineligible C.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Bortezomib and Lenalidomide (RVD-Lite) Consolidation Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/781-bortezomib-and-lenalidomide-rvd-lite-consolidation-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00781a</strong></p>
<p>Treatment of newly diagnosed multiple myeloma patients who are transplant ineligible after completion of RVD-lite induction therapy.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Cyclophosphamide 2000mg/m<sup>2</sup><span> </span>For Stem Cell Mobilisation</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/438-cyclophosphamide-2000mg-m2-for-stem-cell-mobilisation.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00438a</strong></p>
<p><span>Mobilisation of peripheral blood stem cells for future stem cell rescue following high dose chemotherapy</span></p>
</td>
</tr>
<tr>
<td>
<p><strong>Cyclophosphamide 1500mg/m2 For Stem Cell Mobilisation</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/795-cyclophosphamide-for-stem-cell-mobilisation.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00795a</strong></p>
<p>Mobilisation of peripheral blood stem cells for future stem cell rescue following high dose chemotherapy.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Lenalidomide Maintenance Therapy (RVD-Lite)</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/782-lenalidomide-maintenance-therapy-rvd-lite-.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00782a</strong></p>
<p>Indicated as single agent maintenance therapy in patients with newly diagnosed multiple myeloma patients who are transplant ineligible after completion of RVD-lite induction and consolidation therapy.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Bortezomib, Thalidomide and Dexamethasone (VTD) Induction Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/274-bortezomib-thalidomide-and-dexamethasone-vtd-induction-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00274a</strong></p>
<p>Bortezomib, thalidomide and dexamethasone for induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Carfilzomib and Dexamethasone (Kd) Therapy-28day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/566-carfilzomib-and-dexamethasone-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00566a</strong></p>
<p>Carfilzomib in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy</p>
</td>
</tr>
<tr>
<td>
<p><strong>Carfilzomib (20/70mg/m<sup>2</sup> once Weekly) Dexamethasone (Kd) Therapy-28 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/595-carfilzomib-20-70mg-m2-once-weekly-with-dexamethasone-kd-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00595a</strong></p>
<p>Carfilzomib in combination with dexamethasone is indicated for<br/>the treatment of adult patients with multiple myeloma who<br/>have received at least one prior therapy</p>
</td>
</tr>
<tr>
<td>
<p><strong>Carfilzomib (56mg/m<sup>2</sup>  once weekly) Lenalidomide and Dexamethasone (KRd) Therapy -  28 day</strong></p>
<p> <a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/598-carfilzomib-56mg-m2-once-weekly-lenalidomide-and-dexamethasone-krd-therapy-28-day.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00598a</strong></p>
<p>Carfilzomib,  lenalidomide and dexamethasone therapy is indicated  for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Carfilzomib (27mg/m<sup>2</sup> twice weekly), Lenalidomide and Dexamethasone (KRd) Therapy - 28 day</strong></p>
<p> <a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/405-carfilzomib-lenalidomide-and-dexamethasone-krd-therapy-28-day.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00405a</strong></p>
<p>Carfilzomib,  lenalidomide and dexamethasone therapy is indicated  for the treatment of adult patients with multiple myeloma who have received at least one prior therapy</p>
</td>
</tr>
<tr>
<td>
<p><strong>CyBorD/ Cylophosphamide, Bortezomib, and Dexamethasone-21 day Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/273.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00273a</strong></p>
<p>Treatment of newly diagnosed symptomatic multiple myeloma*</p>
<p><strong>00273b</strong></p>
<p>Treatment of relapsed/refractory multiple myeloma*</p>
</td>
</tr>
<tr>
<td>
<p><strong>Modified CyBord/ Bortezomib/ Cyclophosphamide and Dexamethasone – weekly therapy</strong></p>
<p> <a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/299-modified-cybord-bortezomib-cyclophosphamide-and-dexamethasone-%E2%80%93-weekly-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00299a</strong></p>
<p>Treatment of newly diagnosed symptomatic multiple myeloma.</p>
<p><strong>00299b</strong></p>
<p>Treatment of relapsed/refractory multiple myeloma.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Cyclophosphamide 2000mg/m2 For Stem Cell Mobilisation </strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/438-cyclophosphamide-2000mg-m2-for-stem-cell-mobilisation.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00438a</strong></p>
<p>Mobilisation of peripheral blood stem cells for future stem cell rescue following high dose chemotherapy.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Daratumumab Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/daratumumab monotherapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00426a</strong></p>
<p>As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Daratumumab S/C Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/604-daratumumab-s-c-monotherapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00604a</strong></p>
<p>As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy</p>
</td>
</tr>
<tr>
<td>
<p><strong>Daratumumab (IV), Bortezomib and Dexamethasone Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/560-daratumumab-iv-bortezomib-and-dexamethasone-therapy1.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00560a</strong></p>
<p>Daratumumab in combination with bortezomib and dexamethasone in adult patients with multiple myeloma who have received at least one prior therapy</p>
</td>
</tr>
<tr>
<td>
<p><strong>Daratumumab (SC 1800mg), Bortezomib and Dexamethasone Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/609-daratumumab-s-c-bortezomib-and-dexamethasone-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00609a</strong></p>
<p>Daratumumab in combination with bortezomib and dexamethasone in adult patients with multiple myeloma who have received at least one prior therapy</p>
</td>
</tr>
<tr>
<td>
<p><strong>Daratumumab (SC 1800mg), Bortezomib (weekly) and Dexamethasone Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/695-daratumumab-sc-1800mg-bortezomib-weekly-and-dexamethasone-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00695a</strong></p>
<p>Daratumumab in combination with bortezomib and dexamethasone in adult patients with mulitple myeloma who have received at least one prior therapy</p>
</td>
</tr>
<tr>
<td>
<p><strong>Daratumumab SC, Bortezomib, Thalidomide and Dexamethasone Induction Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/703-daratumumab-bortezomib-thalidomide-and-dexamethsone-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00703a</strong></p>
<p>Daratumumab in combination with bortezomib, thalidomide and dexamethasone for the treatment of adults with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant</p>
</td>
</tr>
<tr>
<td>
<p><strong>Daratumumab SC, Bortezomib, Thalidomide and Dexamethasone Consolidation Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/755-daratumumab-sc-bortezomib-twice-weekly-thalidomide-and-dexamethasone-consolidation-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00755a</strong></p>
<p>Daratumumab in combination with bortezomib, thalidomide and dexamethasone for the treatment of adults with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant</p>
</td>
</tr>
<tr>
<td>
<p><strong>Daratumumab (SC), Bortezomib (Once Weekly), Thalidomide and Dexamethasone Induction Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/752-daratumumab-sc-bortezomib-once-weekly-thalidomide-and-dexamethasone-induction-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00752a</strong></p>
<p>Daratumumab in combination with bortezomib, thalidomide and dexamethasone for the treatment of adults with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant</p>
</td>
</tr>
<tr>
<td>
<p><strong>Daratumumab (SC), Bortezomib (Once Weekly), Thalidomide and Dexamethasone Consolidation Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/756-daratumumab-sc-bortezomib-once-weekly-thalidomide-and-dexamethasone-consolidation-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00756a</strong></p>
<p>Daratumumab in combination with bortezomib, thalidomide and dexamethasone for the treatment of adults with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant</p>
</td>
</tr>
<tr>
<td>
<p><strong>Ixazomib, Lenalidomide and Dexamethasone Therapy -  28 day</strong></p>
<p> <a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/516-ixazomib-lenalidomide-and-dexamethasone-therapy-28-day.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00516a</strong></p>
<p>Ixazomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy</p>
</td>
</tr>
<tr>
<td>
<p><strong>Lenalidomide 25mg and Dexamethasone Therapy-28 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/218-lenalidomide-25mg-and-dexamethasone-therapy-28-day.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00218a</strong></p>
<p>Treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.</p>
<p><strong>00218b</strong></p>
<p>Treatment of multiple myeloma in adult patients who have received at least one prior therapy.</p>
</td>
</tr>
<tr>
<td>
<p><strong>High Dose Melphalan Conditioning Therapy for Autologous Stem Cell Transplant</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/454-high-dose-melphalan-conditioning-therapy-for-autologous-stem-cell-transplant.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00454a</strong></p>
<p>Conditioning Therapy in patients with Multiple Myeloma prior to autologous stem cell transplant </p>
<p><strong>00454b</strong></p>
<p>Conditioning Therapy in patients with other plasma cell dyscrasia such as AL amyloidosis</p>
</td>
</tr>
<tr>
<td>
<p><strong>Plerixafor and G-CSF Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/536-plerixafor-and-g-csf-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00536a</strong></p>
<p>Is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma and multiple myeloma whose cells mobilise poorly </p>
</td>
</tr>
<tr>
<td>
<p><strong>Pomalidomide and Dexamethasone</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/245-pomalidomide-and-dexamethasone.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00245a</strong></p>
<p>Treatment in combination with dexamethasone of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Pomalidomide, Bortezomib and Dexamethasone (PVD) Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/601-pomalidomide-bortezomib-and-dexamethasone-pvd-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00601a</strong></p>
<p>Pomalidomide in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior treatment including lenalidomide</p>
</td>
</tr>
<tr>
<td colspan="2">* Unlicensed indication.  See regimen for further information</td>
</tr>
<tr>
<td colspan="2">** Unlicensed posology.  See regimen for further information</td>
</tr>
</tbody>
</table><table border="1" cellpadding="1" cellspacing="2" height="155" summary="list of renal protocols" width="831">
<thead>
<tr align="left" valign="top">
<th id="th0CE300280000"><strong><strong>Regimen </strong>Name</strong></th>
<th id="th0CE300280001"><strong>Indication</strong></th>
</tr>
</thead>
<tbody>
<tr align="left" valign="top">
<td>
<p><strong>Everolimus Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/320-everolimus-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00320b</strong></p>
<p>Treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease.</p>
<p><strong>00320c</strong></p>
<p>The treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal origin in adults with progressive disease</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>SUNItinib 37.5mg Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/neuroendocrine/327-sunitinib-37-5mg-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00327a</strong></p>
<p>Treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pNET) with disease progression in adults<br/><br/></p>
</td>
</tr>
</tbody>
</table><table border="1" cellpadding="1" cellspacing="2" height="447" summary="list of renal protocols" width="836">
<thead>
<tr align="left" valign="top">
<th id="th0CE300280000"><strong>Regimen Name</strong></th>
<th id="th0CE300280001"><strong>Indication</strong></th>
</tr>
</thead>
<tbody>
<tr align="left" valign="top">
<td>
<p><strong>Procarbazine Lomustine and VinCRIStine (PCV) Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/neuro-oncology/379-pcv-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00379a</strong></p>
<p>Adjuvant treatment of Grade II glioma administered after radiotherapy.</p>
<p><strong>00379b</strong></p>
<p>Palliative treatment for recurrent high grade gliomas.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Procarbazine, Lomustine and VinCRIStine (PCV) Therapy – 56 days</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/neuro-oncology/658.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00658a</strong></p>
<p>Adjuvant treatment of Grade II glioma administered after radiotherapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Lomustine and Bevacizumab 5mg/kg Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/neuro-oncology/742-lomustine-and-bevacizumab-5mg-kg-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00742a</strong></p>
<p>For the treatment of recurrent malignant glioblastoma.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Temozolomide with Radiotherapy (RT) and Adjuvant Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/neuro-oncology/334-temozolomide-with-radiotherapy-rt-and-adjuvant-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00334a</strong></p>
<p>Adult patients with newly-diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) followed by adjuvant treatment commencing 4 weeks after completion of chemoradiation .</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Temozolomide with Radiotherapy (RT) and Adjuvant Therapy-Patients greater than 65 years</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/neuro-oncology/461temozolomide-with-radiotherapy-rt-and-adjuvant-therapy-patients-greater-than-65-years.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00461a</strong></p>
<p>Adult patients greater than 65 years with newly-diagnosed glioblastoma multiforme not suitable for the standard radiotherapy regimen in combination with temozolomide <sup>ii</sup></p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Temozolomide Recurrent Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/neuro-oncology/342-temozolomide-recurrent-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00342a</strong></p>
<p>Adult patients with Grade III or IV malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.</p>
</td>
</tr>
</tbody>
</table><table border="1" cellpadding="1" cellspacing="2">
<tbody>
<tr>
<td><strong>Regimen Name</strong></td>
<td><strong>Indication</strong></td>
</tr>
<tr>
<td>
<p><strong>Abiraterone and Prednisolone Therapy </strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/103-abiraterone-and-prednisolone-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00103a</strong></p>
<p>Abiraterone is indicated in combination with prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.</p>
<p><strong>00103b</strong></p>
<p>Treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated</p>
</td>
</tr>
<tr>
<td>
<p><strong>Abiraterone 1000mg and Prednisolone 5mg Therapy </strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/577.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00577a</strong></p>
<p>Abiraterone is indicated with prednisone or prednisolone for: the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT)</p>
</td>
</tr>
<tr>
<td>
<p><strong> Afatinib Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/221.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00221a</strong></p>
<p>Treatment of Epidermal Growth Factor Receptor (EGFR) TKI- naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).</p>
</td>
</tr>
<tr>
<td>
<p><strong>Acalabrutinib Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/656-acalabrutinib-monotherapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong></strong><strong>00656a</strong></p>
<p>As monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy</p>
<p><strong>00656b</strong></p>
<p>As monotherapy for the treatment of previously untreated CLL in the presence of 17p deletion or TP53 mutation in adult patients unsuitable for chemoimmunotherapy</p>
</td>
</tr>
<tr>
<td>
<p><strong> Alectinib Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/401 .pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00401a</strong></p>
<p>Treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib</p>
<p><strong> 00401b</strong></p>
<p> As monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)</p>
</td>
</tr>
<tr>
<td>
<p><strong>Anastrozole Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/254.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00254a</strong></p>
<p>Treatment of hormone receptor positive locally advanced or metastatic breast cancer in post-menopausal women. </p>
<p><strong> 00254b</strong></p>
<p>Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer</p>
<p><strong> 00254c</strong></p>
<p>Extended adjuvant treatment of hormone-dependent-invasive breast cancer in postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Apalutamide Therapy </strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/574.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00574a</strong></p>
<p>Apalutamide is indicated for the treatment of adult men with nonmetastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Axitinib Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/axitinib104.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00104a</strong></p>
<p>Treatment of adult patients with advanced renal cell carcinoma (RCC) after failure, on a previous line of therapy, i.e. treatment with SUNItinib, or a cytokine</p>
</td>
</tr>
<tr>
<td>
<p><strong>Pembrolizumab 200mg and Axitinib Therapy </strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/583.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00583a</strong></p>
<p>Pembrolizumab in combination with axitinib for the first-line treatment of advanced renal cell carcinoma (RCC) in adults.</p>
</td>
</tr>
<tr>
<td>
<p><strong> Bicalutamide Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/482-bicalutamide-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00482a</strong></p>
<p>Treatment of advanced prostate cancer in combination with luteinizing-hormone releasing hormone (LHRH) analogue therapy or surgical castration</p>
</td>
</tr>
<tr>
<td>
<p><strong> Bortezomib , Melphalan and Prednisolone</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/275-bortezomib-melphalan-and-prednisolone-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00275a</strong></p>
<p>Treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Bortezomib + Dexamethasone +Thalidomide (VTD) Induction Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/274-bortezomib-thalidomide-and-dexamethasone-vtd-induction-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00274a</strong></p>
<p>Bortezomib, thalidomide and dexamethasone for induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation</p>
</td>
</tr>
<tr>
<td>
<p><strong> Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy- 21 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/416.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00416a</strong></p>
<p>Treatment of newly diagnosed myeloma in adult patients with high risk features</p>
<p><strong>00416b</strong></p>
<p>Treatment of relapsed or refractory myeloma that has received prior therapy in adult patients with high risk features</p>
</td>
</tr>
<tr>
<td>
<p><strong> Bortezomide, Cyclophosphamide and Dexamethasone -21 day Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/273.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00273a</strong></p>
<p>Treatment of newly diagnosed symptomatic multiple myeloma. </p>
<p><strong> 00273b</strong></p>
<p>Treatment of relapsed/refractory multiple myeloma</p>
</td>
</tr>
<tr>
<td>
<p><strong>Bortezomib, Lenalidomide and Dexamethasone (RVD-Lite) Induction Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/oral-anti-cancer-medicines/780-bortezomib-lenalidomide-and-dexamethasone-rvd-lite-induction-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00780a</strong></p>
<p>Treatment of newly diagnosed multiple myeloma patients who are transplant ineligible C</p>
</td>
</tr>
<tr>
<td>
<p><strong>Bortezomib and Lenalidomide (RVD-Lite) Consolidation Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/oral-anti-cancer-medicines/781-bortezomib-and-lenalidomide.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00781a</strong></p>
<p>Treatment of newly diagnosed multiple myeloma patients who are transplant ineligible after completion of RVD-lite induction therapy.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Lenalidomide Maintenance Therapy (RVD-Lite)</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/oral-anti-cancer-medicines/782%20.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00782a</strong></p>
<p>Indicated as single agent maintenance therapy in patients with newly diagnosed multiple myeloma patients who are transplant ineligible after completion of RVD-lite induction and consolidation therapy.</p>
</td>
</tr>
<tr>
<td>
<p><strong> Bosutinib Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/224-bosutinib-monotherapy-regimen.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00224a</strong></p>
<p>Treatment of adult patients with chronic phase (CP), accelerate phase (AP), and blast phase (BP) Philadelphia choromosome positive chronic myelogenous leukaemia (Ph+CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotonib and dasatinib are not considered appropriate treatment options</p>
</td>
</tr>
<tr>
<td>
<p><strong>Brigatinib Therapy </strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/562-brigatinib-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00562a</strong></p>
<p>For the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib</p>
<p><strong>00562b</strong></p>
<p>Monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor</p>
</td>
</tr>
<tr>
<td>
<p><strong> Cabozantanib Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/518 cabozantinib therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00518a</strong></p>
<p>Treatment of advanced renal cell carcinoma (RCC) in adults following prior VEGF targeted therapy</p>
</td>
</tr>
<tr>
<td>
<p><strong> Capecitabine Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/216.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00216a</strong></p>
<p>Treatment of patients with locally advanced or metastatic breast cancer</p>
<p><strong>00216b</strong></p>
<p>Treatment of metastatic colorectal cancer. </p>
<p><strong> 00216c</strong></p>
<p>Adjuvant treatment of patients following surgery of stage III colon cancer </p>
<p><strong> 00216d</strong></p>
<p>Adjuvant treatment of patients following surgery of stage II colon cancer. </p>
<p><strong> 00216e</strong></p>
<p>Adjuvant treatment of patients with metastatic colorectal cancer following complete resection </p>
<p><strong>00216f</strong></p>
<p>Adjuvant treatment of stage I to IIIB, triple negative breast cancer (TNBC) in patients with residual invasive disease after neoadjuvant chemotherapy treatment</p>
</td>
</tr>
<tr>
<td>
<p><strong>Capecitabine and RT – 7 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/523-capecitabine-and-rt%E2%80%937-day.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00523a</strong></p>
<p>Locally advanced pancreatic cancer after induction chemotherapy</p>
</td>
</tr>
<tr>
<td>
<p><strong>Capecitabine and Temozolomide Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/505.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00505a</strong></p>
<p>Treatment of patients with locally advanced or metastatic neuroendocrine tumours of the pancreas.</p>
</td>
</tr>
<tr>
<td>
<p><strong> Capecitabine/Oxaliplatin (XELOX) Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/321.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00321a</strong></p>
<p>Adjuvant treatment of stage III (Dukes C) colon cancer after complete resection of the primary tumour.</p>
<p><strong> 00321b</strong></p>
<p>Treatment of advanced or metastatic colorectal cancer</p>
<p><strong> 00321c</strong></p>
<p>Adjuvant Stage II/III gastric adenocarcinoma post D2 gastrectomy.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Capecitabine 825mg/m2 and RT–7 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/586-capecitabine-825mg-m2-and-rt%E2%80%937-day.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00586a</strong></p>
<p>Locally advanced rectal cancer</p>
</td>
</tr>
<tr>
<td>
<p><strong> CARBOplatin and Oral Etoposide Therapy-21 days</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/319-carboplatin-and-oral-etoposide-therapy-21-days.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00319a</strong></p>
<p>Small cell lung cancer (SCLC) extensive disease</p>
</td>
</tr>
<tr>
<td>
<p><strong>Carfilzomib (27mg/m<sup>2</sup> twice weekly), Lenalidomide and Dexamethasone (KRd) Therapy - 28 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/405-carfilzomib-lenalidomide-and-dexamethasone-krd-therapy-28-day.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00405a</strong></p>
<p>Carfilzomib, lenalidomide and dexamethasone therapy is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy</p>
</td>
</tr>
<tr>
<td>
<p><strong>Carfilzomib (56mg/m<sup>2</sup> once weekly) Lenalidomide and Dexamethasone (KRd) Therapy - 28 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/598-carfilzomib-56mg-m2-once-weekly-lenalidomide-and-dexamethasone-krd-therapy-28-day.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00598a</strong></p>
<p>Carfilzomib, lenalidomide and dexamethasone therapy is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy</p>
</td>
</tr>
<tr>
<td>
<p><strong> Ceritinib Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/340-ceritinib-monotherapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00340a</strong></p>
<p>Treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib</p>
</td>
</tr>
<tr>
<td>
<p><strong> Chlorambucil10mg/m<sup>2</sup> Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/411-chlorambucil-10mg-m2-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00411a</strong></p>
<p>Treatment of patients with low grade lymphoma. </p>
<p><strong> 00411b</strong></p>
<p>Treatment of patients with Chronic Lymphocytic Leukaemia</p>
</td>
</tr>
<tr>
<td>
<p><strong> CISplatin and Capecitabine Adjuvant Chemoradiation Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/473.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00473a</strong>/p&gt;</p>
<p>Adjuvant treatment of adult patients with resected gastric cancer stage IIA or higher and no distant metastases</p>
</td>
</tr>
<tr>
<td>
<p><strong> CISplatin and Teysuno-28 day cycle</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/235-cisplatin-and-teysuno%C2%AE-28-day-cycle.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00235a</strong></p>
<p>Treatment of advanced gastric cancer when given in combination with CISplatin.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Cobimetinib and Vemurafenib Therapy </strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/cobimetinib and vemurafenib therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00373a</strong></p>
<p>Cobimetinib and vemurafenib in combination are indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.</p>
</td>
</tr>
<tr>
<td>
<p><strong> Crizotinib Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/243-crizotinib-monotherapy-regimen.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00243a</strong></p>
<p>Treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).</p>
<p><strong>00243b</strong></p>
<p>The treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC)</p>
<p><strong>00243c</strong></p>
<p>First-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)</p>
</td>
</tr>
<tr>
<td>
<p><strong><span>Cyclophosphamide</span> (Oral) Methotrexate and 5-Fluorouracil (CMF) Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/377.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00377a</strong></p>
<p>Adjuvant treatment for breast carcinoma in patients who are considered unsuitable for anthracycline therapy</p>
<p><strong> 00377b</strong></p>
<p>Metastatic breast carcinoma</p>
</td>
</tr>
<tr>
<td>
<p><strong> Dabrafenib Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/237dabrafenib.pdf">Regimen</a></p>
</td>
<td>
<p> <strong>00237a</strong></p>
<p>Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation</p>
</td>
</tr>
<tr>
<td>
<p><strong>Dacomitinib Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/565-dacomitinib-monotherapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00565a</strong></p>
<p>Monotherapy, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations </p>
</td>
</tr>
<tr>
<td>
<p><strong>Darolutamide Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/693.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00693a</strong></p>
<p><span>Treatment of adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.</span></p>
</td>
</tr>
<tr>
<td>
<p><strong> Dexamethasone, riTUXimab and Cyclophosphamide<br/> (DRC)Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/532-dexamethasone-rituximab-and-cyclophosphamide-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00532a</strong></p>
<p>Treatment of Symptomatic treatment naive or relapsed/refractory<br/>Waldenstrom’s macroglobulinaemia</p>
</td>
</tr>
<tr>
<td>
<p><strong> Encorafenib and Binimetinib Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/563-envorafenib-and-binimetinib-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00563a</strong></p>
<p>Treatment of adult patients with advanced unresectable or metastatic)<br/> melanoma with a BRAF V600 mutation.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Entrectinib Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/702-entrectinib-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00703a</strong></p>
<p>As monotherapy for the treatment of adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors</p>
</td>
</tr>
<tr>
<td>
<p><strong> Enzalutamide Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/233-enzalutamide-monotherapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00233a</strong></p>
<p>Treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after DOCEtaxel therapy.</p>
<p><strong>00233b</strong></p>
<p>Treatment of adult men with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated</p>
<p><strong> 00233c</strong></p>
<p>The treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC)</p>
</td>
</tr>
<tr>
<td>
<p><strong> epiRUBicin, CISplatin and Capecitabine (ECX) Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/380.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00380a</strong></p>
<p>Perioperative treatment of resectable gastric adenocarcinoma</p>
<p><strong> 00380b</strong></p>
<p>Perioperative treatment of resectable gastroesophageal junction adenocarcinoma</p>
<p><strong> 00380c</strong></p>
<p>Perioperative treatment of resectable lower oesophagus adenocarcinoma</p>
<p><strong> 00380d</strong></p>
<p>Palliative therapy for metastatic or locally advanced gastric adenocarcinoma</p>
<p><strong> 00380e</strong></p>
<p>Palliative therapy for metastatic or locally advanced oesphagogastric adenocarcinoma </p>
</td>
</tr>
<tr>
<td>
<p><strong> epiRUBicin, Oxaliplatin and Capecitabine (EOX) Therapy </strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/239.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00239a</strong></p>
<p>Locally advanced or metastatic gastric carcinoma</p>
<p><strong> 00239b</strong></p>
<p>Locally advanced or metastatic oesophageal carcinoma</p>
<p><strong> 00239c</strong></p>
<p>Locally advanced or metastatic gastroesophageal carcinoma</p>
</td>
</tr>
<tr>
<td>
<p><strong> Erlotinib Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/219.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00219a</strong></p>
<p>First-line treatment of patients with locally advanced or metastatic non- small cell lung cancer (NSCLC) with EGFR activating mutations.</p>
<p><strong> 00219b</strong></p>
<p>Switch maintenance treatment in patients with locally advanced or metastatic NSCLC with EGFR activating mutations and stable disease after first-line chemotherapy</p>
<p><strong> 00219c</strong></p>
<p>Treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen.</p>
</td>
</tr>
<tr>
<td>
<p><strong> Escalated Dose BEACOPP 21 day Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/354-escalated-dose-beacopp-21-day-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00354a</strong></p>
<p>Treatment of patients with high risk, advanced stage Hodgkin Lymphoma (IPS ≥ 3)</p>
<p><strong> 00354b</strong></p>
<p>Escalation of treatment of patients with Hodgkin Lymphoma after failure to reach complete metabolic response post 2 cycles of ABVD</p>
</td>
</tr>
<tr>
<td>
<p><strong> Everolimus Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/320-everolimus-monotherapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00320a</strong></p>
<p>Treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy</p>
<p><strong> 00320b</strong></p>
<p>Treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease. </p>
<p><strong> 00320c</strong></p>
<p>The treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal origin in adults with progressive disease</p>
</td>
</tr>
<tr>
<td>
<p><strong> Exemestane Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/376.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00376a</strong></p>
<p>Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer</p>
<p><strong> 00376b</strong></p>
<p>Extended adjuvant treatment of hormone-dependent invasive breast cancer in postmenopausal women who have received prior adjuvant endocrine therapy.</p>
<p><strong> 00376c</strong></p>
<p>Advanced breast cancer after relapse or disease porgression in women with natural or artificially induced post menopausal endocrine status</p>
</td>
</tr>
<tr>
<td>
<p><strong> Everolimus and Exemestane Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/322-everolimus-and-exemestane-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00322a</strong></p>
<p>Treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.</p>
</td>
</tr>
<tr>
<td>
<p><strong> Fludarabine, Cyclophosphamide and riTUXimab (FC Oral+R) Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/oral-anti-cancer-medicines/fludarabine-cyclophosamide-and-rituximab-fc-oral-and-r-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00410a</strong></p>
<p>Treatment of B-cell chronic lymphocytic leukaemia (CLL)</p>
</td>
</tr>
<tr>
<td>
<p><strong> Gefitinib Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/220-gefitinib-monotherapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00220a</strong></p>
<p>Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK</p>
</td>
</tr>
<tr>
<td>
<p><strong> Gemcitabine (1000mg/m<sup>2</sup>) and Capecitabine (830mg/m<sup>2</sup>) Therapy - 28 days</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/524.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00524a</strong></p>
<p>Adjuvant treatment of pancreatic adenocarcinoma after macroscopic complete resection</p>
</td>
</tr>
<tr>
<td>
<p><strong> Gemcitabine + Capecitabine Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/384-gemcitabine-1000mg-m2-and-capecitabine-650mg-m2-therapy-21-day.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00384a</strong></p>
<p>Locally advanced or metastatic pancreatic carcinoma</p>
<p><strong> 00384b</strong></p>
<p>Locally advanced bilary tree carcinoma</p>
</td>
</tr>
<tr>
<td>
<p><strong> Ibrutinib Therapy (CLL/ Waldenstrom's Macroglobulinaemia)</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/296.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00296a</strong></p>
<p>As a single agent for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy</p>
<p><strong> 00296b</strong></p>
<p>As a single agent for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy</p>
<p><strong> 00296c</strong></p>
<p>As a single agent for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy</p>
</td>
</tr>
<tr>
<td>
<p><strong> Ibrutinib Therapy (Mantly Cell Lymphoma)</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/297.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00297a</strong></p>
<p>As a single agent for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL)</p>
</td>
</tr>
<tr>
<td>
<p><strong> Idelalisib and Ofatumumab Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/390.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00390a</strong></p>
<p>In combination with Ofatumumab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy</p>
<p><strong> 00390b</strong></p>
<p>In combination with Ofatumumab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies</p>
</td>
</tr>
<tr>
<td>
<p><strong> Idelalisib and riTUXimab Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/389.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00389a</strong></p>
<p>In combination with riTUXimab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy</p>
<p><strong> 00389b</strong></p>
<p>In combination with riTUXimab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies</p>
</td>
</tr>
<tr>
<td>
<p><strong> Idelalisib Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/oral-anti-cancer-medicines/idelalisib-monotherapy-v3-291.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00291a</strong></p>
<p>Monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment. </p>
</td>
</tr>
<tr>
<td>
<p><strong> Imatinib Therapy-GIST</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/335-imatinib-therapy-gist.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00335a</strong></p>
<p>Treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).</p>
<p><strong> 00335b</strong></p>
<p>Adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST</p>
</td>
</tr>
<tr>
<td>
<p><strong> Ixazomib, Lenalidomide and Dexamethasone Therapy - 28 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/myeloma/516-ixazomib-lenalidomide-and-dexamethasone-therapy-28-day.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00516a</strong></p>
<p>Ixazomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy</p>
</td>
</tr>
<tr>
<td>
<p><strong> Lapatinib and Capecitabine</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/217.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00217a</strong></p>
<p>Treatment of adult patients with breast cancer, whose tumours over express HER2 in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which should have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting</p>
</td>
</tr>
<tr>
<td>
<p><strong>Larotrectinib Monotherapy- Adult</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/tumour agnostic therapy/758-larotrectinib-monotherapy-adult.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00758a</strong></p>
<p>For the treatment of adult patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion,</p>
<ul>
<li>who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and</li>
<li>who have no satisfactory treatment options</li>
</ul>
</td>
</tr>
<tr>
<td>
<p><strong>Larotrectinib Monotherapy-Paediatric</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/tumour agnostic therapy/760 larotrectinib-monotherapy-paediatric.pdf">Regimen</a></p>
</td>
<td>
<p><strong>P00760a</strong></p>
<p>For the treatment of paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, <strong></strong></p>
<ul>
<li>who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and</li>
<li>who have no satisfactory treatment options</li>
</ul>
</td>
</tr>
<tr>
<td>
<p><strong> LEAM Autologous Transplant Conditioning Protocol </strong>(Lomustine, etoposide, cytarabine, melphalan)</p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/468-leam-autologous-transplant.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00468a</strong></p>
<p>Autologous conditioning in non-Hodgkins Lymphoma (NHL)</p>
<p><strong> 00468b</strong></p>
<p>Autologous conditioning in Hodgkins lymphoma</p>
</td>
</tr>
<tr>
<td>
<p><strong> Lenalidomide 25mg and Dexamethasone Therapy - 28 day </strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/218.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00218a</strong></p>
<p>Treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant</p>
<p><strong> 00218b</strong></p>
<p>Treatment of multiple myeloma in adult patients who have received at least one prior therapy</p>
</td>
</tr>
<tr>
<td>
<p><strong> Lenvatinib DTC Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/295.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00295a</strong></p>
<p>Treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Lenvatinib-HCC Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/644-lenvatinib-hcc-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00644a</strong></p>
<p>As monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy</p>
</td>
</tr>
<tr>
<td>
<p><strong> Letrozole Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/371.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00371a</strong></p>
<p>Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer</p>
<p><strong> 00371b</strong></p>
<p>Extended adjuvant treatment of hormone-dependent invasive breast cancer in postmenopausal women who have received prior adjuvant endocrine therapy for 5 years.</p>
<p><strong> 00371c</strong></p>
<p>Advanced breast cancer after relapse or disease progression in women with natural or artificially induced post menopausal endocrine status</p>
<p><strong> 00371d</strong></p>
<p>Neo-adjuvant treatment of postmenopausal women with hormone receptor positive breast cancer</p>
</td>
</tr>
<tr>
<td>
<p><strong>Lorlatinib Therapy </strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/570 lorlatinib therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00570a</strong></p>
<p>As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), following disease progression on</p>
<p>(i) alectinib or ceritinib as the first ALK-targeted treatment or </p>
<p>(ii) crizotinib and at least one other ALK-targeted treatment</p>
</td>
</tr>
<tr>
<td>
<p><strong>Midostaurin (DAUNOrubicin and Cytarabine) Induction Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/oral-anti-cancer-medicines/midostaurin-daunorubicin-and-cytarabine-induction-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00682a</strong></p>
<p>Midostaurin is indicated in combination with standard DAUNOrubicin and cytarabine induction<br/>chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Midostaurin and Intermediate Dose Cytarabine Consolidation Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/oral-anti-cancer-medicines/midostaurin-and-intermediate-dose-cytarabine-consolidation-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00683</strong></p>
<p>Midostaurin is indicated in combination with intermediate dose cytarabine consolidation chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive. </p>
</td>
</tr>
<tr>
<td>
<p><strong>Midostaurin Maintenance Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/oral-anti-cancer-medicines/midostaurin-maintenance-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00661</strong></p>
<p>Midostaurin is indicated as single agent maintenance therapy for adult patients with FLT3 mutation positive acute myeloid leukaemia (AML) in complete response after completion of induction and consolidation chemotherapy.</p>
</td>
</tr>
<tr>
<td>
<p><strong>mitoMYcin and Capecitabine Chemoradiation Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/oral-anti-cancer-medicines/727-mitomycin-and-capecitabine-chemoradiation-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00727</strong></p>
<p>Treatment of anal canal carcinoma</p>
</td>
</tr>
<tr>
<td>
<p><strong> Modified CyBorD/ Bortezomib, <span>Cyclophosphamide</span> and Dexamethasone –Weekly Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/299-modified-cybord-bortezomib-cyclophosphamide-and-dexamethasone-%E2%80%93-weekly-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00299a</strong></p>
<p>Treatment of newly diagnosed symptomatic multiple myeloma</p>
<p><strong> 00299b</strong></p>
<p>Treatment of relapsed/refractory multiple myeloma</p>
</td>
</tr>
<tr>
<td>
<p><strong> Nindetanib Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/372.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00372a</strong></p>
<p>Treatment of adult patients with locally advanced, metastatic of stage IIIB or IV, or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy</p>
</td>
</tr>
<tr>
<td>
<p><strong>Niraparib Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/571-niraparib-monotherapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00571a</strong></p>
<p>As monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian cancer who are in response (complete response or partial response) to platinum-based chemotherapy</p>
<p><strong>00571b</strong></p>
<p>As monotherapy for the maintenance treatment of adult patients with platinum sensitive fallopian tube cancer who are in response (complete response or partial response) to platinum-based chemotherapy</p>
<p><strong>00571c</strong></p>
<p>As monotherapy for the maintenance treatment of adult patients with platinum sensitive primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy</p>
</td>
</tr>
<tr>
<td>
<p><strong> Obinutuzumab and Chlorambucil Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/286 obinutuzumab-and-chlorambucil-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00286a</strong></p>
<p>Treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Olaparib (Tablet) Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00588a</strong></p>
<p>Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2‐mutated (germline and/or somatic) high grade epithelial ovarian cancer who are in response (complete or partial) following completion of first‐line platinum based chemotherapy</p>
<p><strong>00588b</strong></p>
<p>Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2‐mutated (germline and/or somatic) fallopian tube cancer who are in response (complete or partial) following completion of first‐line platinum based chemotherapy</p>
<p><strong>00588c</strong></p>
<p>Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2‐mutated (germline and/or somatic) primary peritoneal carcinoma who are in response (complete or partial) following completion of first‐line platinum based chemotherapy</p>
<p><strong>00588d</strong></p>
<p>Maintenance treatment of adult patients with platinum -sensitive relapsed <em>BRCA</em>-mutated (germline and/or somatic) -high grade serous epithelial ovarian cancer who are in response (complete response or partial response) to platinum-based chemotherapy.</p>
<p><strong>00588e</strong></p>
<p>Maintenance treatment of adult patients with platinum -sensitive relapsed <em>BRCA</em>-mutated (germline and/or somatic) fallopian tube cancer who are in response (complete response or partial response) to platinum-based chemotherapy.</p>
<p><strong>00588f</strong></p>
<p>Maintenance treatment of adult patients with platinum -sensitive relapsed <em>BRCA</em>-mutated (germline and/or somatic)  primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy.</p>
</td>
</tr>
<tr>
<td>
<p><strong> Oral Etoposide Therapy </strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/388.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00388a</strong></p>
<p>Small cell lung cancer (SCLC) extensive disease in patients unsuitable for intravenous or combination chemotherapy </p>
</td>
</tr>
<tr>
<td>
<p><strong> Oral Vinorelbine Monotherapy-7days</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/259.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00259a</strong></p>
<p>Advanced breast cancer</p>
<p><strong> 00259b</strong></p>
<p> Non small cell lung cancer (NSLC)</p>
</td>
</tr>
<tr>
<td>
<p><strong>Osimertinib</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/353-osimertinib-monotherapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00353a</strong></p>
<p>Treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC)</p>
<p><strong>00353b</strong></p>
<p>First-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations</p>
</td>
</tr>
<tr>
<td>
<p><strong> Palbociclib Therapy-28 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/414-palbociclib-therapy-28-days.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00414a</strong></p>
<p>Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor</p>
<p><strong> 00414b</strong></p>
<p>Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in women who have received prior endocrine therapy</p>
</td>
</tr>
<tr>
<td>
<p><strong> Pazopanib Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/445-pazopanib-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00445a</strong></p>
<p>First line treatment of advanced Renal Cell Carcinoma (RCC) in adults and for patients who have received prior cytokine therapy for advanced disease.</p>
<p><strong> 00445b</strong></p>
<p>Treatment of adult patients with selective subtypes of advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy. </p>
</td>
</tr>
<tr>
<td>
<p><strong> Pomalidomide and Dexamethasone</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/245-pomalidomide-and-dexamethasone.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00245a</strong></p>
<p>Treatment in combination with dexamethasone of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.</p>
</td>
</tr>
<tr>
<td>
<p><strong> Ponatinib Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/302.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00302a</strong></p>
<p>Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation </p>
<p><strong>00302b</strong></p>
<p>Treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation. </p>
</td>
</tr>
<tr>
<td>
<p><strong> Procarbazine Lomustine and VinCRIStine (PCV) Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/oral-anti-cancer-medicines/procarbazine-lomustine-and-vincristine-pcv-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00379a</strong></p>
<p>Adjuvant treatment of Grade II glioma administered after radiotherapy </p>
<p><strong> 00379b</strong></p>
<p>Palliative treatment for recurrent high grade gliomas </p>
</td>
</tr>
<tr>
<td>
<p><strong>Procarbazine, Lomustine and VinCRIStine (PCV) Therapy – 56 days</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/neuro-oncology/658.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00658a</strong></p>
<p>Adjuvant treatment of Grade II glioma administered after radiotherapy.</p>
</td>
</tr>
<tr>
<td>
<p><strong> RiTUXimab, Cyclophosphamide, Etoposide, Vincristine Prednisolone (R-CEOP) Therapy – 21 days</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/510-r-ceop-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00510a</strong></p>
<p>Treatment of Non Hodgkin CD20 positive Lymphoma for patients not</p>
</td>
</tr>
<tr>
<td>
<p><strong> Regorafenib Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/244.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00244a</strong></p>
<p>Treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy. </p>
<p><strong> 00244b</strong></p>
<p>Treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib</p>
</td>
</tr>
<tr>
<td>
<p><strong> Ribociclib Therapy-28 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/525-ribociclib-therapy-28-day.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00525a</strong></p>
<p>Treatment of postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer as initial endocrine-based therapy in combination with an aromatase inhibitor.</p>
<p><strong>00525b</strong></p>
<p>Treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine based therapy or in women who have received prior endocrine therapy.</p>
<p>In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.</p>
</td>
</tr>
<tr>
<td>
<p><strong> Ruxolitinib Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/229-ruxolitinib-monotherapy-regimen.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00229a</strong></p>
<p>Treatment of disease related splenmegaly or symptoms in adult patients with primary myelofibrosis (chronic idiopathic myelofibrosis)</p>
<p><strong> 00229b</strong></p>
<p>Post polycythaemia vera myelofibrosis</p>
<p><strong> 00229c</strong></p>
<p>Post essential thrombocythaemia myelofibrosis</p>
</td>
</tr>
<tr>
<td>
<p><strong> Sorafenib Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/294-sorafenib-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00294a</strong></p>
<p>Treatment of hepatocellular carcinoma (HCC).</p>
<p><strong> 00294b</strong></p>
<p>Treatment of patients with advanced renal cell carcinoma (RCC) who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.</p>
<p><strong> 00294c</strong></p>
<p>Treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine.</p>
</td>
</tr>
<tr>
<td>
<p><strong> SUNitnib 37.5mg Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/neuroendocrine/327-sunitinib-37-5mg-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00327a</strong></p>
<p>Treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pNET) with disease progression in adults </p>
</td>
</tr>
<tr>
<td>
<p><strong> SUNitinib 50mg Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/325-sunitnib-50mg-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00325a</strong></p>
<p>Treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due to resistance or intolerance. </p>
<p><strong> 00325b</strong></p>
<p>Treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults </p>
</td>
</tr>
<tr>
<td>
<p><strong>SUNitinib 50mg (21 Days) Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/oral-anti-cancer-medicines/sunitinib-50mg-therapysunitinib 50mg therapy .pdf">Regimen</a></p>
</td>
<td>
<p><strong>00719a</strong></p>
<p>Treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due to resistance or intolerance. </p>
<p><strong>00719b</strong></p>
<p>Treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults </p>
</td>
</tr>
<tr>
<td>
<p><strong>Talazoparib</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/605-talazoparib-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00605a</strong></p>
<p>Talazoparib is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy or be considered unsuitable for endocrine-based therapy.</p>
</td>
</tr>
<tr>
<td>
<p><strong> Tamoxifen Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/253tamoxifen.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00253a</strong></p>
<p>Adjuvant treatment of oestrogen receptor positive breast cancer in pre- or post-menopausal women.</p>
<p><strong> 00253b</strong></p>
<p>Treatment of oestrogen receptor positive advanced breast cancer in pre- or post-menopausal women </p>
</td>
</tr>
<tr>
<td>
<p><strong> Temozolomide Recurrent Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/neuro-oncology/342-temozolomide-recurrent-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00342a</strong></p>
<p>Adult patients with Grade III or IV malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma,showing recurrence or progression after standard therapy.</p>
</td>
</tr>
<tr>
<td>
<p><strong> Temozolomide with Radiotherapy (RT) and Adjuvant Therapy-Patients greater than 65 years</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/neuro-oncology/461temozolomide-with-radiotherapy-rt-and-adjuvant-therapy-patients-greater-than-65-years.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00461a</strong></p>
<p>Adult patients greater than 65 years with newly-diagnosed glioblastoma multiforme not suitable for the standard radiotherapy regimen in combination with temozolomide. </p>
</td>
</tr>
<tr>
<td>
<p><strong> Temozolomide with RT and Adjuvant Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/neuro-oncology/334-temozolomide-with-radiotherapy-rt-and-adjuvant-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00334a</strong></p>
<p>Adult patients with newly-diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) followed by adjuvant treatment commencing 4 weeks after completion of chemoradiation.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Tivozanib Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/564-tivozanib-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00564a</strong></p>
<p>Tivozanib for the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC</p>
</td>
</tr>
<tr>
<td>
<p><strong>Topotecan Oral Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/587-topotecan-oral-monotherapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00587a</strong></p>
<p>Treatment of adult patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first –line regimen is not considered appropriate</p>
</td>
</tr>
<tr>
<td>
<p><strong>Trametinib and Dabrafenib Therapy </strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/dabrafenib and trametinib therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00415a</strong></p>
<p>Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.</p>
</td>
</tr>
<tr>
<td>
<p><strong> Tretinoin (ATRA) with Arsenic Trioxide (ATO) Induction Therapy </strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/356-tretinoin-atra-with-arsenic-trioxide-ato-induction-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00356a</strong></p>
<p>Treatment of patients with newly diagnosed low to intermediate risk Acute Promyelocytic Leukaemia (APL)</p>
</td>
</tr>
<tr>
<td>
<p><strong> Tretinoin (ATRA) with Arsenic Trioxide (ATO) Consolidation Therapy </strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/357-tretinoin-atra-with-arsenic-trioxide-ato-consolidation-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00357a</strong></p>
<p>Treatment of patients with low to intermediate risk Acute Promyelocytic Leukaemia (APL) with haematological complete remission (CR) after induction treatment with tretinoin (ATRA) and arsenic trioxide (Ref NCCP Protocol 00356</p>
</td>
</tr>
<tr>
<td>
<p><strong> Tretinoin (ATRA)/Idarubicin (PETHEMA AIDA) Induction Therapy </strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/366-tretinoin-atra-idarubicin-pethema-aida-induction-therapy-high-risk.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00366a</strong></p>
<p>Treatment of patients with newly diagnosed Acute Promyelocytic Leukaemia (APL)</p>
</td>
</tr>
<tr>
<td>
<p><strong> Trifluridine and Tipiracil (Lonsurf®) Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/382.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00382a</strong></p>
<p>Treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine, oxaliplatin and irinotecan based therapies, anti-VEGF and anti-EGFR agents. </p>
</td>
</tr>
<tr>
<td>
<p><strong> Vandetanib Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/242vandetanibmonotherapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00242a</strong></p>
<p>Treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.</p>
</td>
</tr>
<tr>
<td>
<p><strong> Vemurafenib Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/102-vemurafenib-monotherapy-regimen.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00102a</strong></p>
<p>Treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.</p>
</td>
</tr>
<tr>
<td>
<p><strong> Venetoclax Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/400.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00400a</strong></p>
<p>Treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor</p>
<p><strong> 00400b</strong></p>
<p>Treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor</p>
</td>
</tr>
<tr>
<td>
<p><strong>Venetoclax and riTUXimab Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/575-venetoclax-and-rituximab-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00575a</strong></p>
<p>Venetoclax in combination with riTUXimab is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy</p>
</td>
</tr>
<tr>
<td>
<p><strong> Vismodegib Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/236.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00236a</strong></p>
<p>Treatment of adult patients with symptomatic metastatic basal cell carcinoma (MBCC)</p>
<p><strong> 00236b</strong></p>
<p>Treatment of adult patients with local advanced basal cell carcinoma inappropriate for surgery or radiotherapy</p>
</td>
</tr>
<tr>
<td>
<p><strong>Zanubrutinib Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/oral-anti-cancer-medicines/708-zanubrutinib_v1.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00708</strong></p>
<p>As monotherapy for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM), who have received at least one prior therapy or<br/>as first line treatment for patients unsuitable for chemo-immunotherapy</p>
</td>
</tr>
</tbody>
</table><table border="0" height="325" width="834">
<tbody>
<tr>
<td><strong>Regimen</strong></td>
<td><strong>Indication</strong></td>
</tr>
<tr>
<td>
<p><strong>Blinatumomab Paediatric Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/paediatric/567.pdf">Regimen</a></p>
</td>
<td>
<p><strong>P0567a</strong></p>
<p>As monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogenic hematopoietic stem cell transplantation</p>
</td>
</tr>
<tr>
<td>
<p><strong><strong> Blinatumomab for Relapsed Paediatric ALL: Consolidation Therapy</strong></strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/paediatric/707-blinatumomab-rall-consolidation-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>P00707a</strong><strong></strong></p>
<p>As monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome negative CD19 positive B-precursor acute lymphoblastic leukaemia (ALL) as part of the consolidation therapy.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Dinutuximab beta and Isotretinoin Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/paediatric/dinutuximab-v2-p548.pdf">Regimen</a></p>
</td>
<td>
<p><strong>P0548a</strong></p>
<p>For the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease. Prior to the treatment of relapsed neurobasltoma, any actively progressing disease should be stabilised by other suitable measures.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Larotrectinib Monotherapy-Paediatric</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/tumour agnostic therapy/760 larotrectinib-monotherapy-paediatric.pdf">Regimen</a></p>
</td>
<td>
<p><strong>P00760a</strong></p>
<p>For the treatment of paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion,</p>
<ul>
<li><strong></strong>who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and</li>
<li>who have no satisfactory treatment options</li>
</ul>
</td>
</tr>
</tbody>
</table><table border="1" cellpadding="1" cellspacing="2" height="1171" summary="list of protocols" width="821">
<thead>
<tr align="left" valign="top">
<th id="th095D50080000">Regimen Name</th>
<th id="th095D50080001"><strong>Indication</strong></th>
</tr>
</thead>
<tbody>
<tr align="left" valign="top">
<td>
<p><strong>Dacarbazine (1.2 g/m<sup>2</sup>) Therapy –21 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/511-dacarbazine-1-2-g-m2-therapy-%E2%80%9321-day.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00511a</strong></p>
<p>Treatment of metastatic soft tissue sarcoma</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>DOXOrubicin 75mg/m<sup>2</sup> Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/500-doxorubicin-75mg-m2-monotherapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00500a</strong></p>
<p>Treatment of locally advanced unresectable or metastatic soft tissue sarcoma.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>DOXOrubicin (25mg/m<sup>2</sup>/day and CISplatin (100mg/m2) Therapy-21 day cycle</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/420-doxorubicin-25mg-m2-day-and-cisplatin-100mg-m2-therapy-21-day-cycle.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00420a</strong></p>
<p>Neoadjuvant/Adjuvant therapy of osteosarcoma.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>DOXOrubicin (60) and Ifosfamide Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/391.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00391a</strong></p>
<p>Treatment of locally advanced unresectable or metastatic soft tissue sarcomas.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>DOXOrubicin (75) and Ifosfamide Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/392.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00392a</strong></p>
<p>Neoadjuvant treatment of high risk soft tissue sarcoma.</p>
<p><strong>00392b</strong></p>
<p>Treatment of locally advanced unresectable or metastatic soft tissue sarcomas.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Gemcitabine and DOCEtaxel Therapy* - 21 day</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/501-gemcitabine-and-docetaxel-therapy-21-day.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00501a</strong></p>
<p>Treatment of locally advanced unresectable or metastatic soft tissue sarcoma.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Etoposide</strong><strong> and ifosfamide - vinCRIStine, DOXOrubicin and cyclophosphamide (IE-VAC) Therapy – Two Weekly Intervals</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/675-etoposide-and-ifosfamide-vincristine-doxorubicin-and-cyclophosphamide-ie-vac-therapy.pdf">Regimen</a></p>
</td>
<td>
<p> <strong>00675a</strong></p>
<p>For the treatment of adolescents/young adults with newly diagnosed Ewing Sarcoma/ Ewing Family of tumours</p>
<p><strong>00675b</strong></p>
<p>For the treatment of adolescents/young adults with rhabdomyosarcoma or desmoplastic intra-abdominal small round blue cell tumour.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Etoposide and ifosfamide - vinCRIStine, DOXOrubicin and cyclophosphamide (IE-VAC) Therapy – Three Weekly Intervals</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/747-ie-vac-three-weekly.pdf">Regimen</a></p>
</td>
<td>
<p><strong> 00747a</strong></p>
<p>For the treatment of adult patients with newly diagnosed Ewing Sarcoma/ Ewing Family of tumours.</p>
<p><strong>00747b</strong></p>
<p>For the treatment of adult patients with rhabdomyosarcoma or desmoplastic intra-abdominal small round blue cell tumour.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Ifosfamide Etoposide (IE) Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/596-ifosfamide-etoposide-ie-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00596a</strong></p>
<p>For the treatment of relapsed Ewing Sarcoma.</p>
<p><strong>00596b</strong></p>
<p>For the treatment of osteosarcoma</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Imatinib Therapy-GIST</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/335-imatinib-therapy-gist.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00335a</strong></p>
<p>Treatment of adult patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).</p>
<p><strong>00335b</strong></p>
<p>Adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Infusional Ifosfamide Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/679-infusional-ifosfamide-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00679a</strong></p>
<p>High grade soft tissue sarcoma, retroperitoneal and de-differentiated sarcoma</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>(MAP) Methotrexate (12000mg/m<sup>2</sup>) DOXOrubicin (37.5mg/m<sup>2</sup>/day) and CISplatin (60mg/m<sup>2</sup>) Therapy </strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/463-map-methotrexate-12000mg-m2-doxorubicin-37-5mg-m2-day-and-cisplatin-60mg-m2-therapy1.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00463a</strong></p>
<p>Neoadjuvant/Adjuvant therapy of localised or metastatic high grade osteosarcoma of an extremity/axial skeleton (excluding craniofacial sites)&amp;nbsp; -all disease sites amenable to complete surgical resection</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Mifamurtide</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/100 .pdf">Regimen</a></p>
</td>
<td>
<p><strong>00100a</strong></p>
<p>Treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection, in children, adolescents and young adults.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>PAZOPanib Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/445-pazopanib-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00445b</strong></p>
<p>Treatment of adult patients with selective subtypes of advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Pegylated Liposomal DOXOrubicin 50mg/m2 (CAELYX®) 28 days</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/205-pegylated-liposomal-doxorubicin-50mg-m2-caelyx-%C2%AE-28-days-regimen.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00205a</strong></p>
<p>Monotherapy for patients with metastatic breast cancer.</p>
<p><strong>00205b</strong></p>
<p>Treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen</p>
<p><strong>00205c</strong></p>
<p>Metastatic soft tissue sarcoma</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Pegylated Liposomal DOXOrubicin 20mg/m<sup>2</sup> (CAELYX®) 21 days</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/462.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00462a</strong></p>
<p>Treatment of AIDS-related Kaposi’s sarcoma (KS) in patients with low CD4 counts ( &amp;lt; 200 CD4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Regorafenib Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/244-regorafenib-monotherapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00244b</strong></p>
<p>Treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>SUNitinib 50mg Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/325-sunitnib-50mg-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00325a</strong></p>
<p>Treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due to resistance or intolerance.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>SUNitinib 50mg (21 Days) Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/sunitinib-50mg-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00719a</strong></p>
<p>Treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due toresistance or intolerance.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Trabectedin Monotherapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/374.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00374a</strong></p>
<p>Treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>vinBLAStine and Methotrexate Therapy</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/554-vinblastine-and-methotrexate-therapy.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00554a</strong></p>
<p>Treatment of advanced aggressive fibromatosis</p>
</td>
</tr>
<tr align="left" valign="top">
<td> </td>
</tr>
</tbody>
</table><table border="1" cellpadding="1" cellspacing="2" height="563" summary="list of protocols" width="831">
<thead>
<tr align="left" valign="top">
<th id="th092D6F200000"><strong>Regimen Name</strong></th>
<th id="th092D6F200001"><strong>Indication</strong></th>
</tr>
</thead>
<tbody>
<tr align="left" valign="top">
<td>
<p><strong>Avelumab Monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/535.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00535a</strong></p>
<p>Treatment of adult patients with metastatic Merkel cell carcinoma who have received 1 or more lines of chemotherapy for metastatic disease</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Cobimetinib and Vemurafenib Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/cobimetinib and vemurafenib therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00373a</strong></p>
<p>Cobimetinib in combination with vemurafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Dabrafenib Monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/237dabrafenib.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00237a</strong></p>
<p>Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Dacarbazine Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/464-dacarbazine-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00464a</strong></p>
<p>Treatment of metastatic malignant melanoma.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Encorafenib and Binimetinib Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/563-envorafenib-and-binimetinib-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00563a</strong></p>
<p>Treatment of adult patients with advanced (unresectable or metastatic) melanoma with a BRAF V600 mutation</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Ipilimumab monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/105.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00105a</strong></p>
<p>Treatment of adults with advanced (unresectable or metastatic) malignant melanoma.</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Nivolumab 240mg Monotherapy - 14 Day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/483-nivolumab-240mg-monotherapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00483a</strong></p>
<p>As monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults.</p>
<p><strong>00483f</strong></p>
<p>As monotherapy for the adjuvant treatment of adults with melanoma with<br/>involvement of lymph nodes or metastatic disease who have undergone<br/>complete resection</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Nivolumab 480mg Monotherapy - 28 Day</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/484-nivolumab-480mg-monotherapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00484a</strong></p>
<p>As monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults.</p>
<p><strong>00484c</strong></p>
<p>As monotherapy for the adjuvant treatment of adults with melanoma with<br/>involvement of lymph nodes or metastatic disease who have undergone<br/>complete resection</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Nivolumab 1mg/kg Ipilimumab 3mg/kg Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/431-nivolumab-1mg-ipilimumab-3mg-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00431a</strong></p>
<p>Nivolumab in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Nivolumab 3mg/kg Ipilimumab 1mg/kg Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/551-nivolumab-3mg-ipilimumab-1mg-therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00551b</strong></p>
<p>Nivolumab in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Pembrolizumab 200mg Monotherapy </strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/pembrolizumab%20200mg%20monotherapy%20455.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00455b</strong></p>
<p>As monotherapy for the treatment of adults with unresectable or advanced melanoma.</p>
<p><strong>00455c</strong></p>
<p>For the treatment of ipilimumab-refractory patients with unresectable or advanced metastatic melanoma.</p>
<p><strong>00455g</strong></p>
<p>As monotherapy is indicated for the adjuvant treatment of adults with Stage III melanoma and lymph node involvement who have undergone complete resection.<strong></strong></p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Pembrolizumab 400 mg Monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/pembrolizumab-400mg-monotherapy-558.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00558b</strong></p>
<p>As monotherapy for the treatment of adults with unresectable or advanced melanoma.</p>
<p><strong>00558c</strong></p>
<p>For the treatment of ipilimumab-refractory patients with unresectable or advanced metastatic melanoma</p>
<p><strong>00558g</strong></p>
<p>Adjuvant treatment of adults with stage III melanoma and  lymph node involvement who have undergone complete resection</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Trametinib and Dabrafenib Therapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/dabrafenib and trametinib therapy.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00415a</strong>&lt;</p>
<p>Trametinib in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation</p>
<p><strong>00415b</strong></p>
<p>Trametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Vemurafenib Monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/102-vemurafenib-monotherapy-regimen.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00102a</strong></p>
<p>Treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma</p>
</td>
</tr>
<tr align="left" valign="top">
<td>
<p><strong>Vismodegib Monotherapy</strong></p>
<p><strong><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/236.pdf">Regimen</a></strong></p>
</td>
<td>
<p><strong>00236a</strong></p>
<p>Treatment of adult patients with symptomatic metastatic basal cell carcinoma (MBCC)</p>
<p><strong>00236b</strong></p>
<p>Treatment of adult patients with local advanced basal cell carcinoma inappropriate for surgery or radiotherapy.</p>
</td>
</tr>
</tbody>
</table><table border="1" cellpadding="1" cellspacing="2">
<tbody>
<tr>
<td><strong>Regimen Name</strong></td>
<td><strong>Indication</strong></td>
</tr>
<tr>
<td>
<p><strong>Busulfan/Cyclophosphamide–MAC–MUD</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/639.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00639a</strong></p>
<p>Myeloablative conditioning for matched unrelated donor allogeneic stem cell transplant in patients with myeloid disorders.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Busulfan/Cyclophosphamide – MAC – SIB</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/641.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00641a</strong></p>
<p>Myeloablative conditioning for sibling donor allogeneic stem cell transplant in patients with myeloid disorders.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Busulfan/Cyclophosphamide/ATG Grafalon® – MAC – Mismatched Sibling Donor</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/662.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00662a</strong></p>
<p>Myeloablative conditioning for mismatched sibling donor allogeneic stem cell transplant in patients with myeloid disorders.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Busulfan/Cyclophosphamide/ATG Grafalon® – MAC – Mismatched Unrelated Donor</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/663.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00663a</strong></p>
<p>Myeloablative conditioning for mismatched unrelated donor allogeneic stem cell transplant in patients with myeloid disorders.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-SIB/MUD</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/638.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00638a</strong></p>
<p>Reduced intensity conditioning for sibling or matched unrelated allogeneic stem cell transplantation in Hodgkins and Non-Hodgkins Lymphoma.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Cyclophosphamide/Total Body Irradiation (TBI)–MAC–MUD</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/631.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00631a</strong></p>
<p>Myeloablative conditioning (MAC) for matched unrelated donor allogeneic stem cell transplant in patients with lymphoid disorders and acute or chronic leukaemias.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Cyclophosphamide/Total Body Irradiation (TBI)–MAC–SIB</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/637.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00637a</strong></p>
<p>Myeloablative conditioning (MAC) for sibling donor allogeneic stem cell transplant in patients with lymphoid disorders.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatched Sibling Donor</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/630.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00630a</strong></p>
<p>Myeloablative conditioning (MAC) for mismatched sibling donor allogeneic stem cell transplant in patients with lymphoid disorders.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatched Unrelated Donor</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/629.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00629a</strong></p>
<p>Myeloablative conditioning (MAC) for mismatched unrelated donor allogeneic stem cell transplant in patients with lymphoid disorders and acute or chronic leukaemias.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Fludarabine/Busulfan/ATG Grafalon® – RIC – MUD</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/635.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00635a</strong></p>
<p>Reduced intensity conditioning for matched unrelated donor allogeneic stem cell transplant in patients with myeloid disorders.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Fludarabine/Busulfan/ATG Grafalon® – RIC –SIB</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/636.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00636a</strong></p>
<p>Reduced intensity conditioning for sibling donor allogeneic stem cell transplant in patients with myeloid disorders.</p>
</td>
</tr>
<tr>
<td>
<p><strong>Fludarabine/Melphalan/Alemtuzumab-RIC-MUD</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/625.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00625a</strong></p>
<p>Reduced intensity conditioning for matched unrelated donor allogeneic stem cell transplant in patients with lymphoproliferative disorders. </p>
</td>
</tr>
<tr>
<td>
<p><strong>Fludarabine/Melphalan/Alemtuzumab-RIC-SIB</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/611.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00611a</strong></p>
<p>Reduced intensity conditioning for sibling donor allogeneic stem cell transplant in patients with lymphoproliferative disorders.</p>
</td>
</tr>
</tbody>
</table><table border="1" cellpadding="1" cellspacing="2">
<tbody>
<tr>
<td><strong>Regimen Name</strong></td>
<td><strong>Indication</strong></td>
</tr>
<tr>
<td>
<p><strong>BEAM Autologous Transplant Conditioning Protoco</strong>l</p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/408.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00408a</strong></p>
<p>Autologous conditioning in non-Hodgkins Lymphoma (NHL).</p>
<p><strong>00408b</strong></p>
<p>Autologous conditioning in Hodgkins Lymphoma.</p>
</td>
</tr>
<tr>
<td>
<p><strong>LEAM Autologous Transplant Conditioning Protocol</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/468-leam-autologous-transplant.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00468a</strong></p>
<p>Autologous conditioning in non-Hodgkins Lymphoma (NHL).</p>
<p><strong>00468b</strong></p>
<p>Autologous conditioning in Hodgkins Lymphoma.</p>
</td>
</tr>
<tr>
<td>
<p><strong>High Dose Melphalan Conditioning Therapy for Autologous Stem Cell Transplant</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/transplant/454-high-dose-melphalan-conditioning-therapy-for-autologous-stem-cell-transplant.pdf">Regimen</a></p>
</td>
<td>
<p><strong>00454a </strong></p>
<p>Conditioning Therapy in patients with Multiple Myeloma prior to autologous stem cell transplant.</p>
<p><strong>00454b</strong></p>
<p>Conditioning Therapy in patients with other plasma cell dyscrasia such as AL amyloidosis.</p>
</td>
</tr>
</tbody>
</table><table border="0" height="74">
<tbody>
<tr>
<td><strong>Regimen Name</strong></td>
<td><strong>Indication</strong></td>
</tr>
<tr>
<td>
<p><strong> Larotrectinib Monotherapy - Adult</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/tumour agnostic therapy/758-larotrectinib-monotherapy-adult.pdf">Regimen</a></p>
</td>
<td>
<p> <strong>00758a</strong></p>
<p>For the treatment of adult patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion,</p>
<ul>
<li>who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and</li>
<li>who have no satisfactory treatment options</li>
</ul>
</td>
</tr>
<tr>
<td>
<p><strong>Larotrectinib Monotherapy - Paediatric</strong></p>
<p><a href="/eng/services/list/5/cancer/profinfo/chemoprotocols/tumour agnostic therapy/760 larotrectinib-monotherapy-paediatric.pdf">Regimen</a></p>
</td>
<td>
<p><strong>P00760a</strong></p>
<p>For the treatment of paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion,</p>
<ul>
<li>who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and</li>
<li>who have no satisfactory treatment options</li>
</ul>
</td>
</tr>
<tr>
<td> </td>
<td> </td>
</tr>
</tbody>
</table>